


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:38Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405002" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405002</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>lifesciall</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Life Sci Alliance</journal-id><journal-id journal-id-type="iso-abbrev">Life Sci Alliance</journal-id><journal-id journal-id-type="pmc-domain-id">3573</journal-id><journal-id journal-id-type="pmc-domain">lifesciall</journal-id><journal-id journal-id-type="publisher-id">lsa</journal-id><journal-title-group><journal-title>Life Science Alliance</journal-title></journal-title-group><issn pub-type="epub">2575-1077</issn><publisher><publisher-name>Life Science Alliance LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405002</article-id><article-id pub-id-type="pmcid-ver">PMC12405002.1</article-id><article-id pub-id-type="pmcaid">12405002</article-id><article-id pub-id-type="pmcaiid">12405002</article-id><article-id pub-id-type="pmid">40897471</article-id><article-id pub-id-type="doi">10.26508/lsa.202503249</article-id><article-id pub-id-type="publisher-id">LSA-2025-03249</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>3</subject><subject>12</subject></subj-group></article-categories><title-group><article-title>&#947;&#948; T cells are the prime antitumoral T cells in pediatric neuroblastoma</article-title><alt-title alt-title-type="short">Generation of neuroblastoma-derived TIL products</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9751-980X</contrib-id><name name-style="western"><surname>Castenmiller</surname><given-names initials="SM">Suzanne M</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Writing&#x2014;original draft" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing&#8212;original draft</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Writing&#x2014;review and editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing&#8212;review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Borst</surname><given-names initials="AL">Anne L</given-names></name><xref rid="aff4" ref-type="aff">4</xref><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Writing&#x2014;review and editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing&#8212;review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wardak</surname><given-names initials="L">Leyma</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Writing&#x2014;review and editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing&#8212;review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Molenaar</surname><given-names initials="JJ">Jan J</given-names></name><xref rid="aff4" ref-type="aff">4</xref><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3006-1993</contrib-id><name name-style="western"><surname>Papadopoulou</surname><given-names initials="M">Maria</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff6" ref-type="aff">6</xref><xref rid="aff7" ref-type="aff">7</xref><xref rid="aff8" ref-type="aff">8</xref><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Writing&#x2014;review and editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing&#8212;review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Krijger</surname><given-names initials="RR">Ronald R</given-names></name><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff9" ref-type="aff">9</xref><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Writing&#x2014;review and editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing&#8212;review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>van der Steeg</surname><given-names initials="AFW">Alida FW</given-names></name><xref rid="aff4" ref-type="aff">4</xref><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Writing&#x2014;review and editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing&#8212;review and editing</role></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0503-5838</contrib-id><name name-style="western"><surname>van Noesel</surname><given-names initials="MM">Max M</given-names></name><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff10" ref-type="aff">10</xref><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Writing&#x2014;review and editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing&#8212;review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vermijlen</surname><given-names initials="D">David</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff6" ref-type="aff">6</xref><xref rid="aff7" ref-type="aff">7</xref><xref rid="aff8" ref-type="aff">8</xref><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Writing&#x2014;review and editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing&#8212;review and editing</role></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4070-0848</contrib-id><name name-style="western"><surname>de Groot</surname><given-names initials="R">Rosa</given-names></name><xref rid="aff1" ref-type="aff">1</xref><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Writing&#x2014;review and editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing&#8212;review and editing</role></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3835-6374</contrib-id><name name-style="western"><surname>Wienke</surname><given-names initials="J">Judith</given-names></name><xref rid="aff4" ref-type="aff">4</xref><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Writing&#x2014;review and editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing&#8212;review and editing</role></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3242-1363</contrib-id><name name-style="western"><surname>Wolkers</surname><given-names initials="MC">Monika C</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp"/><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="http://credit.niso.org/" vocab-term="Writing&#x2014;original draft" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing&#8212;original draft</role></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution-wrap><institution>Sanquin Blood Supply Foundation, Department of Research, T Cell Differentiation Lab, Amsterdam, The Netherlands</institution></institution-wrap>
</aff><aff id="aff2">
<label>2</label>
<institution-wrap><institution>Landsteiner Laboratory, Amsterdam Institute for Infection and Immunity, Cancer Center Amsterdam-Cancer Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands</institution></institution-wrap>
</aff><aff id="aff3">
<label>3</label>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/01n92vv28</institution-id><institution>Oncode Institute</institution></institution-wrap>
<institution-wrap><institution>, Utrecht, The Netherlands</institution></institution-wrap>
</aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02aj7yc53</institution-id><institution>Princess M&#225;xima Center</institution></institution-wrap>
<institution-wrap><institution>for Pediatric Oncology, Utrecht, The Netherlands</institution></institution-wrap></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01r9htc13</institution-id><institution>Department of Pharmacotherapy and Pharmaceutics, Universit&#233; Libre de Bruxelles</institution></institution-wrap>
<institution-wrap><institution>(ULB), Brussels, Belgium</institution></institution-wrap></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01r9htc13</institution-id><institution>Institute for Medical Immunology (IMI), Universit&#233; Libre de Bruxelles</institution></institution-wrap>
<institution-wrap><institution>(ULB), Gosselies, Belgium</institution></institution-wrap></aff><aff id="aff7">
<label>7</label>
<institution-wrap><institution>ULB Center for Research in Immunology (U-CRI), Gosselies, Belgium</institution></institution-wrap>
</aff><aff id="aff8">
<label>8</label>
<institution-wrap><institution>WEL Research Institute, WELBIO Department, Wavre, Belgium</institution></institution-wrap>
</aff><aff id="aff9">
<label>9</label>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/0575yy874</institution-id><institution>Department of Pathology, University Medical Center Utrecht</institution></institution-wrap>
<institution-wrap><institution>, Utrecht, The Netherlands</institution></institution-wrap>
</aff><aff id="aff10">
<label>10</label>
<institution-wrap><institution-id institution-id-type="ror">https://ror.org/0575yy874</institution-id><institution>Division Imaging and Cancer, University Medical Center Utrecht</institution></institution-wrap>
<institution-wrap><institution>, Utrecht, The Netherlands</institution></institution-wrap>
</aff><author-notes><corresp id="cor1">Correspondence: <email>m.wolkers@sanquin.nl</email></corresp></author-notes><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><volume>8</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">494801</issue-id><elocation-id>e202503249</elocation-id><history><date date-type="received"><day>5</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>20</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Castenmiller et al.</copyright-statement><copyright-year>2025</copyright-year><ali:free_to_read/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is available under a Creative Commons License (Attribution 4.0 International, as described at <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="LSA-2025-03249.pdf"/><self-uri content-type="reviewer_comments" xlink:href="LSA-2025-03249_review_history.pdf"/><abstract abstract-type="precis"><p>Expanded TIL products generated from pediatric neuroblastoma lesions show antitumor potential, with &#947;&#948; T cells as the main effector cells.</p></abstract><abstract><p>High-risk pediatric neuroblastoma patients have a dismal survival rate despite intensive treatment regimens. New treatment options are thus required. Even though HLA expression in neuroblastoma is low and immune cell infiltrates are limited, the presence of tumor-infiltrating lymphocytes (TILs) is indicative of better patient survival. Here, we show that most tumor lesions contain viable immune cell infiltrates after induction chemotherapy, with high percentages of CD3<sup>+</sup> T cells. We therefore expanded the TILs and tested their antitumoral activity. With sufficient starting material, TIL expansion was as efficient as for adult solid tumors. However, whereas TIL products from adult tumors almost exclusively contained &#945;&#946; T cells, in neuroblastoma-derived TIL products, &#947;&#948; T cells expanded with similar efficacy as &#945;&#946; T cells. Importantly, the antitumor responses in response to autologous tumor digest primarily originated from (V&#948;1- and V&#948;3-expressing) &#947;&#948; T cells, and not from &#945;&#946; T cells. In conclusion, this finding creates a window of opportunity for immunotherapy for neuroblastoma patients, with &#947;&#948; T cells as potential prime responders.</p></abstract><funding-group specific-use="FundRef"><award-group id="gs1"><funding-source id="sp1"><institution-wrap><institution>Stichting Sanquin Bloedvoorziening (Sanquin Blood Supply Foundation)</institution><institution-id institution-id-type="DOI">http://dx.doi.org/10.13039/501100012023</institution-id></institution-wrap></funding-source><award-id rid="sp1">PPOC 21-07</award-id><principal-award-recipient><name name-style="western"><surname>Wolkers</surname><given-names>MC</given-names></name></principal-award-recipient></award-group><award-group id="gs2"><funding-source id="sp2"><institution-wrap><institution>Oncode Institute</institution><institution-id institution-id-type="DOI">http://dx.doi.org/10.13039/501100021821</institution-id></institution-wrap></funding-source><principal-award-recipient><name name-style="western"><surname>Wolkers</surname><given-names>MC</given-names></name></principal-award-recipient></award-group><award-group id="gs3"><funding-source id="sp3"><institution-wrap><institution>Stichting Kinderen Kankervrij (KiKa)</institution><institution-id institution-id-type="DOI">http://dx.doi.org/10.13039/501100006244</institution-id></institution-wrap></funding-source><award-id rid="sp3">KIKA 404,KIKA 491</award-id><principal-award-recipient><name name-style="western"><surname>Wienke</surname><given-names>J</given-names></name><name name-style="western"><surname>Wolkers</surname><given-names>MC</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Neuroblastoma is the most common extracranial solid cancer in children (<xref rid="bib30" ref-type="bibr">Maris et al, 2007</xref>; <xref rid="bib32" ref-type="bibr">Matthay et al, 2016</xref>). High-risk patients receive intensive treatment with debulking chemotherapy, surgical resection, and additional round(s) of high-dose chemotherapy followed by autologous stem cell rescue, radiotherapy, or the recently developed antibody-based anti-GD2 immunotherapy (<xref rid="bib27" ref-type="bibr">Ladenstein et al, 2018</xref>). Yet, their 5-yr survival rate does not exceed 50% (<xref rid="bib32" ref-type="bibr">Matthay et al, 2016</xref>; <xref rid="bib29" ref-type="bibr">Li et al, 2023</xref>), highlighting the urgent need for novel treatment options.</p><p>Neuroblastoma is considered a &#8220;cold&#8221; tumor with low mutational tumor burden, low HLA-I expression, and low immune cell infiltrates (<xref rid="bib43" ref-type="bibr">Pugh et al, 2013</xref>; <xref rid="bib4" ref-type="bibr">Batchu, 2021</xref>; <xref rid="bib60" ref-type="bibr">Wienke et al, 2021</xref>; <xref rid="bib57" ref-type="bibr">Verhoeven et al, 2022</xref>). All this combined impedes the tumor cell recognition by T cells (<xref rid="bib61" ref-type="bibr">W&#246;lfl et al, 2004</xref>). However, encouraged by the effectiveness of the anti-GD2 immunotherapy in neuroblastoma patients (<xref rid="bib65" ref-type="bibr">Yu et al, 2010</xref>; <xref rid="bib53" ref-type="bibr">Theruvath et al, 2022</xref>; <xref rid="bib18" ref-type="bibr">Flaadt et al, 2023</xref>), using the immune system to combat neuroblastoma has recently gained interest (<xref rid="bib27" ref-type="bibr">Ladenstein et al, 2018</xref>; <xref rid="bib68" ref-type="bibr">Zappa et al, 2023</xref>). Enhancing immune responses against neuroblastoma could indeed be powerful for improving the patients&#8217; prognosis.</p><p>Adoptive therapy with tumor-infiltrating lymphocytes (TIL therapy) is coming of age for treating solid tumors (<xref rid="bib47" ref-type="bibr">Rosenberg &amp; Restifo, 2015</xref>; <xref rid="bib46" ref-type="bibr">Rohaan et al, 2022</xref>). Reinfusion of in vitro expanded autologous T cells from tumor lesions achieved high response rates in a phase 3 clinical trial in melanoma patients with disseminated tumors (<xref rid="bib46" ref-type="bibr">Rohaan et al, 2022</xref>). Owing to this success and the recent FDA approval for TIL therapy for melanoma, TIL therapy is currently evaluated in other solid tumors, including non&#8211;small-cell lung cancer (<xref rid="bib5" ref-type="bibr">Ben-Avi et al, 2018</xref>; <xref rid="bib13" ref-type="bibr">De Groot et al, 2019</xref>; <xref rid="bib10" ref-type="bibr">Creelan et al, 2021</xref>; <xref rid="bib8" ref-type="bibr">Castenmiller et al, 2022</xref>), renal cell carcinoma (<xref rid="bib3" ref-type="bibr">Asten et al, 2021</xref>), bladder cancer (<xref rid="bib42" ref-type="bibr">Poch et al, 2018</xref>), and ovarian cancer (<xref rid="bib40" ref-type="bibr">Pedersen et al, 2018</xref>). TIL therapy currently focuses on highly immune-infiltrated &#8220;hot&#8221; tumors with a high mutational burden. Yet, clinical responses were also reported for TIL therapy in so-called &#8220;cold&#8221; tumors with little to limited immune infiltrates and mutational burden, such as breast, ovarian, colorectal, and pancreatic cancers (<xref rid="bib66" ref-type="bibr">Zacharakis et al, 2018</xref>, <xref rid="bib67" ref-type="bibr">2022</xref>; <xref rid="bib25" ref-type="bibr">Kim et al, 2022</xref>; <xref rid="bib2" ref-type="bibr">Amaria et al, 2024</xref>).</p><p>Even though neuroblastoma is considered a &#8220;cold&#8221; tumor, high TIL density positively correlated with the patient outcome (<xref rid="bib4" ref-type="bibr">Batchu, 2021</xref>; <xref rid="bib31" ref-type="bibr">Masih et al, 2021</xref>). Chemotherapy, the standard of care for high-risk neuroblastoma patients, promotes the influx of immune cells into tumors (<xref rid="bib22" ref-type="bibr">Hong et al, 2011</xref>; <xref rid="bib52" ref-type="bibr">Sistigu et al, 2014</xref>). We therefore hypothesized that neuroblastoma lesions after induction chemotherapy contain tumor-reactive T cells that could potentially be used for therapeutic purposes. Here, we report the effective generation of tumor-reactive TIL products from neuroblastoma tumor lesions. Importantly, the composition of pediatric TIL products substantially differed from that of TIL products from adult tumors. Indeed, &#947;&#948; T cells were enriched in neuroblastoma lesions compared with adult tumors, and this enrichment was maintained throughout the expansion protocol. The &#947;&#948; T cells expanded equally well as the &#945;&#946; T-cell receptor&#8211;expressing CD8<sup>+</sup> or CD4<sup>+</sup> T cells. Furthermore, &#947;&#948; T cells were the prime T-cell subset with antitumoral activity. Our findings thus uncover fundamental differences between adult and pediatric neuroblastoma&#8211;derived antitumor responses.</p></sec><sec sec-type="results" id="s2"><title>Results</title><sec id="s3"><title>T cells constitute most of the immune infiltrates in neuroblastoma lesions</title><p>We first studied the immune cell composition of neuroblastoma tumor lesions. We generated single-cell suspensions from 20 tumor lesions obtained from 18 patients after debulking surgery (Table S1). On average, 32.7% of the cells were viable, of which a median of 28.3% &#177; 23.0% were CD45<sup>+</sup> immune cells (<xref rid="fig1" ref-type="fig">Figs 1A&#8211;C</xref> and <xref rid="figS1" ref-type="fig">S1A</xref>). Owing to the cryopreservation of tumor digests before analysis, myeloid cells such as monocytes and neutrophils were underrepresented (<xref rid="figS1" ref-type="fig">Fig S1A</xref>). Of the remaining immune cells, CD3<sup>+</sup> T cells were with a median of 64.5% most abundant (<xref rid="fig1" ref-type="fig">Fig 1D</xref>). Comparative analysis with immunohistochemistry for three samples showed that the percentages obtained with flow cytometry provided a good representation of CD3<sup>+</sup> T-cell infiltrates (<xref rid="figS1" ref-type="fig">Fig S1D</xref>). Monocytes, B cells, NKT cells, and NK cells were also detected, but with highly variable percentages ranging from 0 to 40.2% (<xref rid="fig1" ref-type="fig">Figs 1D</xref>, <xref rid="figS1" ref-type="fig">S1A</xref>, and <xref rid="figS2" ref-type="fig">S2B</xref>).</p><p>
<supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><p>Table S1. <inline-supplementary-material xlink:href="LSA-2025-03249_TableS1.xlsx" id="d67e559" content-type="local-data">Patient sample information.</inline-supplementary-material></p></supplementary-material>
</p><fig position="float" fig-type="featured" id="fig1" orientation="portrait"><label>Figure 1.</label><caption><title>Immune cell composition of pediatric neuroblastoma tumor lesions.</title><p><bold>(A)</bold> Representative gating strategy for analyzing immune cell infiltrates (sample M189AAF_2). <bold>(B, C, D, E)</bold> Percentage of (B) viable cells in neuroblastoma tumor lesions, (C) CD45<sup>+</sup> immune infiltrates of viable cells, (D) different immune cell subsets as the percentage of total viable immune infiltrates, and (E) T-cell subsets as the percentage of total T-cell infiltrate. n = 20 samples; each dot represents one tumor sample. Box-and-whisker plots depict median, minimum, and maximum values (whiskers) and 25th and 75th pct (box).</p></caption><graphic position="float" orientation="portrait" xlink:href="LSA-2025-03249_Fig1.jpg"/></fig><fig position="float" fig-type="supplementary-material" id="figS1" specific-use="collapsible" orientation="portrait"><label>Figure S1.</label><caption><title>Phenotypic analysis of tumor-infiltrating lymphocytes (TILs) ex vivo and upon TIL expansion.</title><p><bold>(A, B)</bold> Table depicting the mean, minimal, and maximal percentage of indicated immune cell subsets measured in (A) defrosted tumor digest (n = 20) and (B) after rapid expansion phase (n = 19 for immune cell subsets, n = 10 for T-cell subsets). Antibodies for phenotypic analysis are indicated. <bold>(C)</bold> Schematic overview of used patient samples during this study, and the reasons for sample exclusion for future data analysis. <bold>(D)</bold> Ex vivo immunohistochemistry for three representative tumor samples (sample M350AAB, low CD3 [L]; sample M959AAB, medium CD3 [M]; and sample M978AAC, high CD3 [H]); CD3-positive cells are stained red. The results from IHC and flow cytometry are compared in the graph. <bold>(E)</bold> Gating strategy for immune cell subsets in expanded TIL products (sample M583AAB). <bold>(F)</bold> Graphs from <xref rid="fig2" ref-type="fig">Fig 2A, D&#8211;G</xref>, with the two outliers identified with blue (sample M990AAC) and purple (sample M223AAD). Each dot represents one tumor sample. Box-and-whisker plots depict median, minimum, and maximum values (whiskers) and 25th and 75th pct (box).</p></caption><graphic position="float" orientation="portrait" xlink:href="LSA-2025-03249_FigS1.jpg"/></fig><fig position="float" fig-type="supplementary-material" id="figS2" specific-use="collapsible" orientation="portrait"><label>Figure S2.</label><caption><title>Marker expression on ex vivo tumor-infiltrating lymphocytes.</title><p><bold>(A)</bold> scRNA expression profile for ex vivo IL-2RA and IL-2RB on different T-cell subsets from neuroblastoma lesions. <bold>(B)</bold> Expression of CD56 and CD16 on ex vivo tumor-infiltrating lymphocytes from neuroblastoma lesions treated with collagenase IV, on neuroblastoma tumor cells treated with collagenase IV, and on PBMCs untreated with collagenase IV. <bold>(C)</bold> Characteristics from adult tumor lesions used in <xref rid="fig2" ref-type="fig">Fig 2</xref>.</p></caption><graphic position="float" orientation="portrait" xlink:href="LSA-2025-03249_FigS2.jpg"/></fig><p>CD3<sup>+</sup> T-cell infiltrates in neuroblastoma lesions primarily consisted of &#945;&#946; CD8<sup>+</sup> T cells and conventional &#945;&#946; CD4<sup>+</sup> T cells (Tconv), together accounting for a median of 80% of CD3<sup>+</sup> T cells (<xref rid="fig1" ref-type="fig">Figs 1E</xref> and <xref rid="figS1" ref-type="fig">S1A</xref>). CD127<sup>low</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells (Tregs) were detected in 17 out of 20 (85%) tumor lesions, yet with low percentages (<xref rid="fig1" ref-type="fig">Figs 1E</xref> and <xref rid="figS1" ref-type="fig">S1A</xref>). We also detected &#947;&#948; T cell infiltrates with a median of 9.2%, comprising up to 36% of the CD3<sup>+</sup> T cells in one tumor lesion (<xref rid="fig1" ref-type="fig">Figs 1E</xref> and <xref rid="figS1" ref-type="fig">S1A</xref>). Of note, the percentage of &#947;&#948; T cells of CD3<sup>+</sup> T cells reflects the percentages of &#947;&#948; T cells reported in tissues of children (<xref rid="bib21" ref-type="bibr">Gray et al, 2024</xref>). The high variability in CD45<sup>+</sup> cell infiltrates and its composition could not be attributed to different disease stages (LR, low risk; MR, medium risk; HR, high risk) or different treatment regimens (Table S1). This finding contrasts significantly with the dogma that neuroblastomas are immunologically &#8220;cold&#8221; tumors, because almost all tumors contained immune infiltrates upon debulking chemotherapy, and the infiltrates primarily consist of T cells.</p></sec><sec id="s4"><title>TILs can be effectively expanded from neuroblastoma lesions</title><p>Having established that T cells are present in neuroblastoma lesions, we tested their capacity to expand. A recent study reported successful TIL expansion from neuroblastoma lesions (<xref rid="bib36" ref-type="bibr">Hurtado et al, 2019</xref>); however, limited tumor reactivity had been observed (<xref rid="bib36" ref-type="bibr">Hurtado et al, 2019</xref>). Because &#945;CD3/&#945;CD28 activation was used immediately for T cell expansion (<xref rid="bib36" ref-type="bibr">Hurtado et al, 2019</xref>), this protocol may have favored the expansion of T cells from contaminating blood, or of non&#8211;tumor-reactive, bystander tissue-resident T cells that are amply present in solid tumors (<xref rid="bib51" ref-type="bibr">Simoni et al, 2018</xref>; <xref rid="bib28" ref-type="bibr">Li et al, 2022</xref>). This in turn may hamper the outgrowth of tumor-reactive, yet to some degree dysfunctional, T cells. We therefore used the rapid expansion protocol (REP [<xref rid="bib6" ref-type="bibr">Besser et al, 2010</xref>; <xref rid="bib17" ref-type="bibr">Dudley et al, 2010</xref>]), which for the first 2 wk of culture (pre-REP) uses only the addition of recombinant human IL-2 for TIL expansion from tumor digests (<xref rid="bib56" ref-type="bibr">Berg et al, 2020</xref>; <xref rid="bib46" ref-type="bibr">Rohaan et al, 2022</xref>). This culture setup allows for specific antigen presentation from the tumor cells in the pre-REP phase and is considered to support the survival and expansion of tumor-specific T cells, which should express the IL-2 receptor (<xref rid="figS2" ref-type="fig">Fig S2A</xref>) (<xref rid="bib56" ref-type="bibr">Berg et al, 2020</xref>; <xref rid="bib46" ref-type="bibr">Rohaan et al, 2022</xref>).</p><p>TILs from neuroblastoma lesions expanded on average 15-fold during the pre-REP phase, and 200-fold during the second 2 wk of expansion with &#945;CD3 and IL-2 (REP phase), resulting in a total expansion of &#8764;1,500-fold (<xref rid="fig2" ref-type="fig">Fig 2A</xref>). However, the efficiency of TIL expansion was not uniform. Whereas 9 out of 20 (45%) TIL cultures expanded less than 500-fold (<xref rid="fig2" ref-type="fig">Fig 2A</xref>), 11 out of 20 (55%) TIL cultures expanded about 3,000-fold (<xref rid="fig2" ref-type="fig">Fig 2A</xref>), which is comparable to the TIL expansion rate reported for adult tumors (<xref rid="bib13" ref-type="bibr">De Groot et al, 2019</xref>; <xref rid="bib8" ref-type="bibr">Castenmiller et al, 2022</xref>; <xref rid="bib46" ref-type="bibr">Rohaan et al, 2022</xref>). When we compared the patient&#8217;s age (in months) at the time of tumor resection, we found a slight association with the efficiency of TILs to expand (<xref rid="fig2" ref-type="fig">Fig 2B</xref>, left panel). Treatment intensity negatively correlated with TIL expansion (<xref rid="fig2" ref-type="fig">Fig 2B</xref>, middle panel). Most prominently, the number of cells that were available for starting the TIL cultures significantly correlated with TIL expansion (<xref rid="fig2" ref-type="fig">Fig 2B</xref>, right panel). Low cell numbers primarily stemmed from tumor needle biopsies as input material (Table S1). In sum, we conclude that sufficient starting material from tumor lesions is pivotal to achieve efficient TIL expansion.</p><fig position="float" fig-type="figure" id="fig2" orientation="portrait"><label>Figure 2.</label><caption><title>Expansion potential and composition of tumor-infiltrating lymphocyte (TIL) products from neuroblastoma lesions.</title><p><bold>(A)</bold> Left: schematic overview of the expansion protocol. Right: fold expansion (right) of TILs during the first 10&#8211;13 d of the pre-rapid expansion phase (pre-REP; left), during the second 10&#8211;13 d (REP; middle), and pre-REP and REP combined (Total; right). The dotted line indicates 500-fold expansion, n = 20. <bold>(B)</bold> Correlation plots between total expansion (y-axis) and patients&#8217; age in months at the time of tissue collection (left), treatment intensity based on the total number of treatments received before surgery (middle), and total cell count of the starting material for TIL expansion (right). r<sub>s</sub> and adjusted <italic toggle="yes">P</italic>-values are indicated in each plot. <italic toggle="yes">P</italic>-values were corrected for six multiple comparisons using the Bonferroni method. Red dots indicate expansion below 500-fold (n = 9). <bold>(C)</bold> Percentage of viable cells in TIL products (n = 20). <bold>(D)</bold> Percentage of CD45<sup>+</sup> cells in TIL products (n = 19; one sample was excluded because of insufficient expansion). <bold>(E, F)</bold> Percentage of indicated immune cell subsets as the percentage of CD45<sup>+</sup> cells, and (F) T cell subsets as the percentage of CD3<sup>+</sup> cells. <bold>(G)</bold> Total fold expansion for CD8<sup>+</sup>, Tconv, and &#947;&#948; T cell subsets. <bold>(E, F, G)</bold> n = 10; only TIL products with high percentages of CD45<sup>+</sup> cells were included. <bold>(H)</bold> Indicated T-cell subsets as the percentage of CD3<sup>+</sup> T cells ex vivo (n = 20) and after REP (n = 10). <bold>(I)</bold> &#947;&#948; T-cell content as the percentage of CD3<sup>+</sup> T cells ex vivo (dots) and upon REP (squares) for adult tumor samples (melanoma, n = 2; non&#8211;small-cell lung cancer, n = 3; renal cell carcinoma, n = 3) and for neuroblastoma (n = 10). Each dot represents one sample. Box-and-whisker plots depict median, minimum, and maximum values (whiskers) and 25th and 75th pct (box). Correlation plots depict the simple linear regression line with the 95th pct coincidence interval (dotted line).</p></caption><graphic position="float" orientation="portrait" xlink:href="LSA-2025-03249_Fig2.jpg"/></fig><p>We next phenotyped the TIL products after REP culture (<xref rid="figS1" ref-type="fig">Fig S1B and E</xref>). Cell viability of the 19 measured TIL products was on average 65.84%, yet with high variability. Well-expanding TIL products (&gt;500-fold) reached a median of 82.5% viability on average, which is above the threshold for clinical use (<xref rid="fig2" ref-type="fig">Fig 2C</xref>, black dots; <xref rid="figS1" ref-type="fig">Fig S1B</xref>). Poorly expanded TIL products (&lt;500-fold) contained low numbers of CD45<sup>+</sup> cells (0&#8211;12.5%). In contrast, well-expanding TIL products contained 64.0&#8211;91.7% CD45<sup>+</sup> cells, and in nine samples, &gt;90% of the CD45<sup>+</sup> cells were CD3<sup>+</sup> T cells (<xref rid="fig2" ref-type="fig">Fig 2D and E</xref>, black dots; <xref rid="figS1" ref-type="fig">Fig S1B</xref>). Only two TIL products with &lt;100-fold expansion contained high percentages of viable cells (<xref rid="figS1" ref-type="fig">Fig S1F</xref>, <italic toggle="yes">colored dots</italic>), of which one contained almost exclusively CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup> T cells (<xref rid="figS1" ref-type="fig">Fig S1F</xref>, <italic toggle="yes">blue dot</italic>). CD19<sup>+</sup> B cells and Foxp3<sup>+</sup>CD4<sup>+</sup> T cells were absent in well-expanding TIL products, and only 2 out of 10 well-expanding TIL products contained low but detectable CD11c<sup>+</sup> or CD16<sup>+</sup> cells (<xref rid="fig2" ref-type="fig">Figs 2E</xref> and <xref rid="figS1" ref-type="fig">S1B</xref>). Thus, well-expanding TIL products contain high numbers of immune cells, of which the majority consists of T cells.</p><p>Interestingly, when we compared the composition of CD3<sup>+</sup> T-cell subsets in the tumor digest ex vivo with that of the expanded TIL products, we observed that the distribution between CD8<sup>+</sup> T cells, Tconv cells, and &#947;&#948; T cells was similar (<xref rid="fig1" ref-type="fig">Figs 1E</xref> and <xref rid="fig2" ref-type="fig">2F</xref>; Table S1), indicating that the three T cell subsets expanded in a similar fashion (<xref rid="fig2" ref-type="fig">Fig 2G</xref>). We next compared the TIL composition from the neuroblastoma lesions with TILs from adult solid tumors (melanoma, NSCLC, RCC; <xref rid="figS2" ref-type="fig">Fig S2C</xref>). Even though adult TILs also contained &#947;&#948; T cell infiltrates ex vivo, as previously reported (<xref rid="bib20" ref-type="bibr">Girard et al, 2019</xref>; <xref rid="bib62" ref-type="bibr">Wu et al, 2019</xref>, <xref rid="bib63" ref-type="bibr">2022</xref>), their percentages were lower than in pediatric neuroblastoma lesions (<xref rid="fig2" ref-type="fig">Fig 2H</xref>). Furthermore, &#947;&#948; T cells derived from adult tumor lesions failed to expand (<xref rid="fig2" ref-type="fig">Fig 2H and I</xref>). Thus, only &#947;&#948; T cells from pediatric neuroblastoma expanded well with the REP. In sum, TIL products can be generated from neuroblastoma lesions, yet its efficiency depends on the quantity of the starting material. In addition, the generated TIL products display a similar composition of effector T cells measured ex vivo.</p></sec><sec id="s5"><title>Expanded TILs from neuroblastoma display childhood-specific cytokine expression patterns</title><p>To test the functionality of TILs that were expanded from neuroblastoma lesions (<xref rid="figS1" ref-type="fig">Fig S1C</xref>), we focused on the well-expanded TIL products. All CD8<sup>+</sup> TILs, Tconv TILs, and &#947;&#948; TILs were potent producers of TNF after a 7-h stimulation with PMA/ionomycin (<xref rid="figS3" ref-type="fig">Fig S3A and B</xref>; see <xref rid="fig3" ref-type="fig">Fig 3A</xref> for an unstained control). However, the production of IFN&#947; was highly variable for all three T cell subsets (<xref rid="figS3" ref-type="fig">Fig S3A and B</xref>). Most strikingly, the production of IL-2 upon PMA/ionomycin stimulation was below 20% for CD8<sup>+</sup> T cells and &#947;&#948; T cells, and only four TIL products contained &gt;20% IL-2&#8211;producing Tconv cells (<xref rid="figS3" ref-type="fig">Fig S3A and B</xref>). This limited IL-2 production corroborates with previous reports from blood-derived pediatric T cells (<xref rid="bib49" ref-type="bibr">Schmiedeberg et al, 2016</xref>; <xref rid="bib54" ref-type="bibr">Thome et al, 2016</xref>). Thus, neuroblastoma-derived TIL products can produce cytokines, but do so with lower potency than TIL products generated from adult solid tumors, which show very high production of all three cytokines with PMA/ionomycin stimulation (<xref rid="bib13" ref-type="bibr">De Groot et al, 2019</xref>; <xref rid="bib3" ref-type="bibr">Asten et al, 2021</xref>; <xref rid="bib8" ref-type="bibr">Castenmiller et al, 2022</xref>).</p><fig position="float" fig-type="supplementary-material" id="figS3" specific-use="collapsible" orientation="portrait"><label>Figure S3.</label><caption><title>Tumor-infiltrating lymphocyte (TIL) products are functional and respond to tumor digest irrespective of IFN&#947; pretreatment.</title><p><bold>(A, B)</bold> Representative dot plot and (B) compiled data (n = 9 for TNF and IFN&#947;, n = 8 for IL-2) of cytokine production from expanded TIL products after 7 h of stimulation with PMA/ionomycin by the indicated T-cell subset (sample M583AAB). <bold>(C)</bold> CD137 and CD107a surface expression and TNF and IFN&#947; production by the indicated T-cell subset in expanded TIL products upon culture for 6&#8211;7 h in medium (light gray), or upon exposure to autologous tumor digest in a 1:1 ratio that was left untreated (gray) or incubated overnight with hrIFN&#947; (black). <bold>(D)</bold> Representative dot plot (left) and compiled data (right) of PD-1 and CD137 expression of TILs ex vivo for the indicated T-cell subset. <bold>(E)</bold> Correlation plots of the percentage of tumor-reactive &#947;&#948; T cells (y-axis, defined as each &#947;&#948; T cell that increases the expression of at least one of the four measured markers upon coculture with the autologous tumor digest) with the percentage of &#947;&#948; T cells of total CD3<sup>+</sup> T cells ex vivo, with the patient&#8217;s age at the time of tumor resection, with the percentage of CD137 expression on &#947;&#948; T cells ex vivo, or with the percentage of PD1 expression on &#947;&#948; T cells ex vivo. Each dot represents one TIL product. Box-and-whisker plots depict median, minimum, and maximum values (whiskers) and 25th and 75th pct (box). Correlation plots depict simple linear regression line with 95th pct coincidence interval (dotted line). Paired <italic toggle="yes">t</italic> test; * &lt; 0.05, ** &lt; 0.01.</p></caption><graphic position="float" orientation="portrait" xlink:href="LSA-2025-03249_FigS3.jpg"/></fig><fig position="float" fig-type="figure" id="fig3" orientation="portrait"><label>Figure 3.</label><caption><title>&#947;&#948; T cells display antitumor reactivity against autologous tumor digest.</title><p><bold>(A)</bold> Representative dot plots for expression levels of surface molecules (left, sample M959AAB) and cytokines (right, sample M583AAB) upon 6- to 7-h culture with medium alone, or with autologous tumor digest in a 1:1 ratio. <bold>(B)</bold> Compiled data of CD137, CD107a, TNF, and IFN&#947; expression on indicated T-cell subsets after culture with medium (M) or with autologous tumor digest (T). Each dot represents one tumor-infiltrating lymphocyte product (n = 10). Wilcoxon&#8217;s test; * &lt; 0.05, ** &lt; 0.01. <bold>(C)</bold> Compiled data of CD137, CD107a, TNF, and IFN&#947; expression of &#947;&#948; tumor-infiltrating lymphocytes after a 6- to 7-h coculture with medium (M), with non-tumorous tissue digest (NT), or with autologous tumor digest in a 1:1 ratio (T). <bold>(D)</bold> Data of (C) normalized to medium control. Each symbol indicates a different patient sample (n = 3). Tukey&#8217;s multiple comparison test; * &lt; 0.05.</p></caption><graphic position="float" orientation="portrait" xlink:href="LSA-2025-03249_Fig3.jpg"/></fig></sec><sec id="s6"><title>Tumor reactivity from neuroblastoma TIL products primarily originates from &#947;&#948; T cells</title><p>We next tested whether the well-expanded TIL products contained tumor-reactive T cells. We exposed the TIL products for 6&#8211;7 h to autologous tumor digest, and we measured the expression of the activation marker CD137 (4-1BB) indicative of TCR triggering (<xref rid="bib64" ref-type="bibr">Ye et al, 2014</xref>), the degranulation marker CD107a, and TNF and IFN&#947; required for effective antitumoral responses (<xref rid="bib39" ref-type="bibr">Patel et al, 2017</xref>) (<xref rid="fig3" ref-type="fig">Fig 3A</xref>). To increase the low HLA expression cells of neuroblastoma cells (<xref rid="bib61" ref-type="bibr">W&#246;lfl et al, 2004</xref>), and thus their capacity to present antigens to T cells, we preexposed the tumor digests overnight with 1,000 IU/ml human recombinant (hr)IFN&#947;, before coculture with the TILs.</p><p>Coculture of TILs with autologous tumor digest resulted in significantly increased CD137 expression in all T-cell subsets when compared to medium control (<xref rid="fig3" ref-type="fig">Fig 3B</xref>; CD8<sup>+</sup> T cells: <italic toggle="yes">P</italic> = 0.02; CD4<sup>+</sup> T cells: <italic toggle="yes">P</italic> = 0.05; &#947;&#948; T cells: <italic toggle="yes">P</italic> = 0.02). This finding indicates that the TCR was engaged. In contrast, CD8<sup>+</sup> T cells and Tconv cells displayed very limited expression of CD107a or production of IFN&#947;, if present at all (<xref rid="fig3" ref-type="fig">Fig 3B</xref>). TNF production was also nearly absent in CD8<sup>+</sup> T cells and limited, yet significantly increased, in Tconv cells (<xref rid="fig3" ref-type="fig">Fig 3B</xref>; <italic toggle="yes">P</italic> = 0.03). In contrast, &#947;&#948; TILs not only significantly increased CD107a expression when exposed to tumor digest (<xref rid="fig3" ref-type="fig">Fig 3B</xref>; <italic toggle="yes">P</italic> = 0.008), but also substantially increased the production of TNF and IFN&#947; (<xref rid="fig3" ref-type="fig">Fig 3B</xref>; TNF: <italic toggle="yes">P</italic> = 0.03; IFN&#947;: <italic toggle="yes">P</italic> = 0.008). Of note, the observed antitumor response of &#947;&#948; TILs did not depend on pretreating tumor digests with hrIFN&#947; (<xref rid="figS3" ref-type="fig">Fig S3C</xref>), suggesting that &#947;&#948; TILs do not react to IFN&#947; response genes. Importantly, the observed &#947;&#948; T-cell responses from neuroblastoma-derived TIL products were tumor-specific, as indicated by the significantly higher expression of CD137 (<italic toggle="yes">P</italic> = 0.02) and a trend in increased CD107a expression when compared to responses to autologous non-tumorous tissue digest (<xref rid="fig3" ref-type="fig">Fig 3C and D</xref>).</p><p>PD-1 and CD137 are two expression markers reported to enrich for tumor-reactive T cells (<xref rid="bib39" ref-type="bibr">Patel et al, 2017</xref>; <xref rid="bib55" ref-type="bibr">Thommen et al, 2018</xref>). Both markers were expressed on a subset of &#947;&#948; T cells ex vivo (<xref rid="figS3" ref-type="fig">Fig S3D</xref>). The PD-1 expression was increased on conventional CD4 T cells, indicating that this T-cell subset also contained some tumor-reactive cells (<xref rid="figS3" ref-type="fig">Fig S3D</xref>). Nevertheless, the CD137 expression was significantly higher on &#947;&#948; T cells than on &#945;&#946; T cells (<xref rid="figS3" ref-type="fig">Fig S3D</xref>). However, neither the percentage of PD-1 nor CD137 ex vivo correlated with tumor reactivity of &#947;&#948; T cells in the TIL product (<xref rid="figS3" ref-type="fig">Fig S3E</xref>). When we correlated the response rates of tumor-reactive &#947;&#948; TILs (e.g., any &#947;&#948; TIL that up-regulated at least one of the four measured markers), we observed a positive trend with the patient&#8217;s age, but not with the percentage of &#947;&#948; T cells ex vivo (<xref rid="figS3" ref-type="fig">Fig S3E</xref>). Thus, &#947;&#948; T cells are the most tumor-reactive T-cell subset in neuroblastoma lesions.</p></sec><sec id="s7"><title>V&#948;1 and V&#948;3 &#947;&#948; T cells are the prime source of antitumor responses</title><p>We next studied which &#947;&#948; T-cell subset contributed most to the antitumor response. &#947;&#948; T cells can be divided into subclasses based on the V&#948; gene used in their TCR (<xref rid="bib11" ref-type="bibr">Davey et al, 2017</xref>; <xref rid="bib44" ref-type="bibr">Ravens et al, 2017</xref>; <xref rid="bib38" ref-type="bibr">Papadopoulou et al, 2020b</xref>). In humans, V&#948;1-, V&#948;2-, and V&#948;3-expressing &#947;&#948; T cells are the most common subtypes (<xref rid="bib38" ref-type="bibr">Papadopoulou et al, 2020b</xref>; <xref rid="bib23" ref-type="bibr">Hu et al, 2023</xref>). We first measured the &#947;&#948; T-cell composition of four expanded TILs with known antitumoral responses (<xref rid="fig4" ref-type="fig">Fig 4A</xref>). The V&#948;1 subtype was most prevalent in three TIL products, and one primarily contained V&#948;2 cells (<xref rid="fig4" ref-type="fig">Fig 4B</xref>). The percentage of V&#948;3 cells was low but present in all four TIL products (<xref rid="fig4" ref-type="fig">Fig 4B</xref>). All &#947;&#948; T-cell subsets were equally equipped to produce TNF and IFN&#947; when stimulated with PMA/ionomycin (<xref rid="fig4" ref-type="fig">Fig 4C and D</xref>; see <xref rid="fig4" ref-type="fig">Fig 4E</xref> for an unstained control). However, when we repeated the coculture with autologous tumor digests, increased CD137 expression was primarily found on V&#948;1 cells and V&#948;3 cells, and much less so on V&#948;2 cells (<xref rid="fig4" ref-type="fig">Fig 4E and F</xref>). Increased CD107a expression was found on all &#947;&#948; T-cell subsets but was most prominent on V&#948;3 cells (<xref rid="fig4" ref-type="fig">Fig 4F</xref>). Cytokine production was also primarily detected on the V&#948;1 and V&#948;3 cells (<xref rid="fig4" ref-type="fig">Fig 4F</xref>). Thus, V&#948;1 and V&#948;3 cells are the prime &#947;&#948; T-cell subsets responding to autologous tumor digests.</p><fig position="float" fig-type="figure" id="fig4" orientation="portrait"><label>Figure 4.</label><caption><title>Tumor-reactive &#947;&#948; T cells primarily consist of the V&#948;1 and V&#948;3 subset.</title><p><bold>(A)</bold> Representative dot plot for V&#948;1, V&#948;2, V&#948;3, and V&#948;4-8 tumor-infiltrating lymphocytes (TILs), pregated on &#947;&#948; T TILs (sample M987AAC). <bold>(B)</bold> Distribution of V&#948;1, V&#948;2, V&#948;3, and V&#948;4-8 as the percentage of total &#947;&#948; T-cell population in four expanded TIL products. &#947;&#948; T-cell subsets were excluded from further analysis when cell numbers were &lt;100 cells. <bold>(C)</bold> Representative FACS plots for cytokine secretion by V&#948;1, V&#948;2, V&#948;3, and V&#948;4-8 TILs after stimulation for 6&#8211;7 h with PMA/ionomycin. <bold>(D)</bold> Compiled data (n = 4). <bold>(E, F)</bold> Representative FACS plots and (F) compiled data of the indicated marker on V&#948;1, V&#948;2, V&#948;3, and V&#948;4-8 TILs after 6&#8211;7 h of coculture with autologous tumor digest in a 1:1 ratio. Each dot represents one TIL product. Box-and-whisker plots depict median, minimum, and maximum values (whiskers) and 25th and 75th pct (box). Wilcoxon&#8217;s test; * &lt; 0.05, ** &lt; 0.01.</p></caption><graphic position="float" orientation="portrait" xlink:href="LSA-2025-03249_Fig4.jpg"/></fig></sec></sec><sec sec-type="discussion" id="s8"><title>Discussion</title><p>We here provide first evidence that TIL products can be generated from pediatric neuroblastoma tumor lesions with the TIL expansion protocol that is used to generate TIL products for melanoma patients (<xref rid="bib13" ref-type="bibr">De Groot et al, 2019</xref>; <xref rid="bib8" ref-type="bibr">Castenmiller et al, 2022</xref>; <xref rid="bib46" ref-type="bibr">Rohaan et al, 2022</xref>). For practical reasons, we used frozen material for TIL expansion. Because the amount of viable cells was the best predictor for effective TIL expansion, and because fresh tumor material generally contains more viable cells, we hypothesize that using fresh material would possibly result in higher efficacy of generating tumor-reactive TIL products.</p><p>Importantly, we report that &#947;&#948; T cells are the prime antitumoral T cells in these TIL products, which show higher response rates to the autologous tumor than to non-tumorous tissue digest. Whereas tumor-responsive CD8<sup>+</sup> T cells in the TIL products failed to produce cytokines, CD4<sup>+</sup> T cells not only displayed increased PD1 expression ex vivo (<xref rid="bib16" ref-type="bibr">Marco et al, 2017</xref>) but also produced TNF in response to autologous tumor digest. This finding suggests CD4<sup>+</sup> T cells could potentially also contribute to antitumoral T-cell responses in neuroblastoma, similar to what was previously reported for several adult solid tumors (<xref rid="bib35" ref-type="bibr">Oja et al, 2017</xref>; <xref rid="bib34" ref-type="bibr">Oh et al, 2020</xref>; <xref rid="bib7" ref-type="bibr">Cachot et al, 2021</xref>; <xref rid="bib33" ref-type="bibr">Nicolet et al, 2021</xref>; <xref rid="bib26" ref-type="bibr">Kruse et al, 2023</xref>).</p><p>For &#947;&#948; T cells, it is yet to be determined how they recognize neuroblastoma cells. The &#947;&#948; TCR does not have the obligate HLA restriction as the conventional &#945;&#946; TCR (<xref rid="bib59" ref-type="bibr">Vermijlen et al, 2018</xref>), and &#947;&#948; T cells can kill target cells upon engagement of NK cell receptors (<xref rid="bib50" ref-type="bibr">Silva-Santos &amp; Strid, 2018</xref>). Whether the activation markers PD-1 and CD137 can be used to identify tumor-reactive T cells in the same fashion for &#947;&#948; T cells as they do for &#945;&#946; T cells is not fully understood. Yet, CD137 was recently used to detect virus-responding &#947;&#948; T cells (<xref rid="bib41" ref-type="bibr">Pei et al, 2020</xref>; <xref rid="bib24" ref-type="bibr">Ji et al, 2024</xref>), and may therefore also be valid to identify tumor-reactive &#947;&#948; T cells. Nevertheless, a more detailed analysis of &#947;&#948; T cells to define the different &#947;&#948; T-cell subtypes, and to profile checkpoint and activation markers, as well as NK cell receptors, is warranted.</p><p>Evidence that &#947;&#948; T cells are contributors to antitumoral responses in solid tumors is recently accumulating. &#947;&#948; T cells are predictive for overall increased survival in non&#8211;small-cell lung cancer and triple-negative breast cancer patients (<xref rid="bib62" ref-type="bibr">Wu et al, 2019</xref>, <xref rid="bib63" ref-type="bibr">2022</xref>). Furthermore, &#947;&#948; T cells respond to checkpoint inhibition and contribute to effective treatment responses in HLA-deficient colon cancer and in melanoma patients with a low mutational rate (<xref rid="bib15" ref-type="bibr">de Vries et al, 2023</xref>; <xref rid="bib12" ref-type="bibr">Davies et al, 2024</xref>). Neuroblastoma is also a tumor with a low mutational rate and low HLA expression. Because the antitumoral &#947;&#948; T-cell responses did not substantially change when tumors were pretreated with hrIFN&#947;, it is conceivable that the tumor recognition of &#947;&#948; T cells occurs independent of HLA. &#947;&#948; T cells responded stronger to autologous tumor than to medium control, similar to what we previously observed for TILs from adult solid tumors (<xref rid="fig3" ref-type="fig">Fig 3C</xref>, [<xref rid="bib13" ref-type="bibr">De Groot et al, 2019</xref>; <xref rid="bib3" ref-type="bibr">Asten et al, 2021</xref>; <xref rid="bib8" ref-type="bibr">Castenmiller et al, 2022</xref>]). However, because the expanded TILs respond more to autologous tumor digest than to fibroblasts, we conclude that these CD137-expressing, cytokine-producing &#947;&#948; T cells are tumor-specific.</p><p>Importantly, the composition and responsiveness of TIL products from neuroblastoma substantially differs from that of TIL products generated from adult tumors. &#947;&#948; TILs expand equally well as the &#945;&#946; T-cell subsets, a feature that was not found in three types of adult solid tumors. This could be related to the inherent higher expansion capacity of &#947;&#948; T cells early after birth (<xref rid="bib37" ref-type="bibr">Papadopoulou et al, 2020a</xref>; <xref rid="bib45" ref-type="bibr">Ravens et al, 2020</xref>; <xref rid="bib19" ref-type="bibr">Giannoni et al, 2024</xref>). In neonates and young children, &#947;&#948; T cells are more diverse (<xref rid="bib11" ref-type="bibr">Davey et al, 2017</xref>). As children age, &#947;&#948; T cells become more oligoclonal, decrease in quantity, and lose their capacity to expand (<xref rid="bib14" ref-type="bibr">De Rosa et al, 2004</xref>; <xref rid="bib48" ref-type="bibr">Schatorj&#233; et al, 2012</xref>; <xref rid="bib9" ref-type="bibr">Clark &amp; Thomas, 2020</xref>). In addition, extrinsic factors could potentially alter the expansion capacity of pediatric &#947;&#948; T cells, such as other immunostimulatory or immunosuppressive cells originating from the tumor digest during TIL expansion. The tumor microenvironment may again differ between pediatric and adult tumors, and even more so in these tumors with low mutational rates and limited inflammatory signature, as is the case for pediatric neuroblastoma.</p><p>Previous studies reported that adult &#947;&#948; T cells may require other cytokines or stimuli in addition to IL-2 for sufficient expansion (<xref rid="bib1" ref-type="bibr">Almeida et al, 2016</xref>; <xref rid="bib58" ref-type="bibr">Verkerk et al, 2024</xref>). Even though we cannot exclude that additional stimuli may even further boost the expansion of &#947;&#948; T cells, we here show that for pediatric &#947;&#948; T cells, IL-2 suffices for expansion. Neuroblastoma patients are overall young and mostly below the age of 10, and this may therefore support the effective expansion of &#947;&#948; T cells with IL-2 alone in our study. In sum, we provide first insights into the difference of adult versus pediatric solid tumor-derived &#947;&#948; T cells. Based on our proof-of-concept study, we propose that &#947;&#948; T cells should be considered for treating pediatric solid tumors, as we showcased here for the feasibility to develop autologous, tumor-reactive TIL products.</p></sec><sec sec-type="materials|methods" id="s9"><title>Materials and Methods</title><sec id="s10"><title>Patient characteristics</title><p>Between February 2020 and January 2022, 19 neuroblastoma patients aged 8&#8211;139 mo (average: 49.6 mo), 11/19 (58%) female, were included in this study. One patient sample (M502AAD) was excluded because of the suspicion of not containing exclusively tumor material but being a lymph node and therefore containing many non&#8211;tumor-specific immune cells (<xref rid="figS1" ref-type="fig">Fig S1C</xref>). The included patients&#8217; characteristics, origin of tumor, and pretreatment regimens are reported in Table S1. Patients were categorized as high risk (HR; n = 12), medium risk (MR; n = 5), and low risk (LR; n = 1). Tumors were resected from adrenal gland (n = 11), soft tissue (n = 4), or other organs (n = 3). One patient (M635AAA) was included in the observation group and received no treatment before debulking surgery. All other patients had received additional treatment before resection, including standard chemotherapy (n = 11), combinations of different chemotherapy regimens (n = 5), combination of chemotherapy with MIBG (n = 2), or chemotherapy followed by autologous stem cell transplantation (n = 1). The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the Princess Maxima Centrum for Pediatric Oncology (Utrecht, The Netherlands) (protocol code MEC-2016-739, and date of approval 13 December 2016). Informed consent was obtained from all subjects involved in the study.</p><p>The adult tumor samples depicted in <xref rid="figS2" ref-type="fig">Fig S2C</xref> were obtained according to the Declaration of Helsinki (seventh revision, 2013), with consent of the Institutional Review Board of the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AvL), Amsterdam, The Netherlands (study number CFMPB317). All subjects provided written informed consent.</p></sec><sec id="s11"><title>Sample collection</title><p>Tumor tissue was obtained directly after surgery and processed within 4 h. Tumor samples (n = 20; from patient M909AAA and M189AAF, two samples from different tumor regions were included) were minced into pieces of 1 mm<sup>3</sup> and digested with collagenase IV (Worthington) for max 1 h at 37&#176;C and filtered over a 70-&#956;m cell strainer to obtain a single-cell suspension. Tumor digest was frozen in liquid nitrogen in 90% FCS/10% DMSO (Corning) until further use.</p></sec><sec id="s12"><title>TIL expansion</title><p>Tumor samples were thawed in 50 ml warm RPMI medium (Gibco) supplemented with 2% FCS (Bodego, Bodinco BV), washed, and cultured in 20/80 T-cell mixed media (Miltenyi) containing 5% FCS, 5% human serum (HS) (Sanquin), 1.25 mg/ml fungizone, and 6,000 IU/ml IL-2 (Proleukin, Novartis). Depending on cell density and cloudiness, cells were cultured in a 24-well (1 ml), 48-well (500 &#956;l), or 96-well (200 &#956;l) plate at 37&#176;C and 5% CO<sub>2</sub> for 12&#8211;14 d, with approximately at a concentration of one million cells per ml. Medium was usually refreshed on days 6, 9, and 12, and cells were split when a monolayer of cells was visible in the entire well. After 12&#8211;14 d, cells were expanded using a down-scaled minor adjusted version of the clinically approved REP (<xref rid="bib46" ref-type="bibr">Rohaan et al, 2022</xref>). Briefly, cells were collected and manually counted (hemocytometer) with trypan blue solution (Sigma-Aldrich). 300,000 viable cells (100,000/well) were cocultured with 5 &#215; 10<sup>6</sup>&#8211;10 &#215; 10<sup>6</sup> irradiated PBMCs pooled from 15 healthy donors (feeder cells) in a 24-well plate, containing 30 ng/ml anti-CD3 antibody (OKT-3; Miltenyi Biotec) and 3,000 IU/ml hrIL-2 for 12&#8211;14 d at 37&#176;C and 5% CO<sub>2</sub>. Medium was refreshed every other day, and cells were split when a monolayer in the entire well was achieved. After 12&#8211;14 d, cells were harvested and manually counted. Expanded cells were cryopreserved in RPMI-1640 medium containing 10% DMSO, 40% FCS until further use.</p></sec><sec id="s13"><title>Tumor reactivity assay</title><p>From the well-expanded TIL products, cryopreserved tumor digest and REP TILs were thawed and incubated in 20/80 T-cell mixed media containing 5% FCS, 5% HS, 1.25 mg/ml fungizone, and 500 IU/ml IL-2 overnight at 37&#176;C to recover from thawing. In addition, tumor digest was stimulated with 100&#8211;1,000 U/ml IFN&#947; (Bio-Techne, R&amp;D Systems) overnight, to increase HLA expression. The next day, cells were counted manually with trypan blue solution. A total of 1 &#215; 10<sup>5</sup> live expanded TILs were cocultured with 1&#8211;2 &#215; 10<sup>5</sup> live tumor digest cells for 7 h at 37&#176;C. As controls, 1 &#215; 10<sup>5</sup> live expanded TILs were stimulated with 10 ng/ml PMA (Sigma-Aldrich) and 1 &#956;g/ml ionomycin (Sigma-Aldrich) or were cultured with T-cell mixed media only. After 1 h of coculture, 1x brefeldin A (Invitrogen) and 1x monensin (Invitrogen) and anti-CD107a BUV395 (BD Biosciences) were added.</p><p>From three patient tumor digest samples, adherent cell cultures could be successfully grown; however, these tissue cell cultures did not contain tumor cells based on single nucleotide polymorphism (SNP) data. Expanded TILs were cocultured with single-cell non-tumorous tissue cells pretreated overnight with hrIFN&#947;.</p></sec><sec id="s14"><title>Flow cytometry analysis</title><p>Flow cytometry analysis was performed on defrosted and washed material. Tumor digest ex vivo was stained with Fixable Viability Dye eFluor 506 (65-0866-14; Thermo Fisher Scientific) for 20 min at 4&#176;C. After washing, cells were stained with the fluorescently labeled surface antibodies (Table S2) in the dark for 20 min at 4&#176;C. After surface staining, cells were fixed and permeabilized using the FOXP3/transcription factor staining buffer set (Invitrogen) and subsequently stained with intracellular antibodies for 30 min at 4&#176;C in the dark. Defrosted PBMCs from 13 adult healthy donors were used for staining controls. Samples were acquired on an Aurora flow cytometer (Cytek Biosciences) with SpectroFlo software.</p><p>
<supplementary-material id="SM2" position="float" content-type="local-data" orientation="portrait"><p>Table S2. <inline-supplementary-material xlink:href="LSA-2025-03249_TableS2.xlsx" id="d67e1269" content-type="local-data">Detailed antibody panels.</inline-supplementary-material></p></supplementary-material>
</p><p>Flow cytometry analysis of expanded TIL products was performed with defrosted material. Cells were stained with antibodies against CD3, CD4, CD8, CD56, TCR&#947;&#948;PAN, and in addition with V&#948;1, V&#948;2, and V&#948;3 for analysis of &#947;&#948; T-cell subsets in a separate experiment. For phenotypic analysis, antibodies against CD11c, CD16, CD19, CD20, CD25, and CD45 were added as well for 30 min at 4&#176;C in the dark (Table S2). Near IR was added for dead cell exclusion. Cells were washed and fixed with the Perm/Fix Foxp3 staining kit (Invitrogen) according to the manufacturer&#8217;s protocol. Cells were stained with antibodies against TNF, IFN, CD137, and IL-2 (T-cell activation) or Foxp3 (phenotypic analysis) for 30 min at 4&#176;C in the dark. Cells were washed twice and passed through a 70-&#956;M single-cell filter before acquisition with the Symphony A5 flow cytometer (BD Biosciences) or the ID7000 spectral cell analyzer (Sony Biotechnologies). A standardized cryopreserved PBMC sample pooled from four healthy donors was included as a control for each measurement. Flow cytometry settings were defined for each patient with single antibody staining. Cell subsets were excluded for further analysis when the cell numbers were below 20 cells (ex vivo) or 100 cells (post-REP); the population was assigned as 0%. Data analysis was carried out with FlowJo Star 10.7.1 (BD).</p></sec><sec id="s15"><title>Immunohistochemistry</title><p>Immunohistochemistry of human neuroblastoma paraffin-embedded tissue slides with hematoxylin and eosin and anti-CD3 was performed by the Pathology Department of the Princess M&#225;xima Center, Utrecht. Tumor tissue slides were pretreated with a citrate solution for 20 min at 100&#176;C, and incubated with the CD3 antibodies for 15 min at RT. The staining was performed on a BOND immunostainer and visualized with the BOND polymer refine detection kit with a DAB enhancer. Analysis of the IHC stainings was performed using QuPath, using automated cell detection with adjusted parameters and subsequent automated cell classification based on CD3 intensity. The number of CD3<sup>+</sup> cells per mm<sup>2</sup> was used as a metric to quantify the amount of CD3<sup>+</sup> cells infiltrating the tumor lesions.</p></sec><sec id="s16"><title>Statistical analysis</title><p>Statistical analysis was carried out with GraphPad Prism 8.0.2 (Dotmatics). Data are shown as single data points with box and whiskers showing maximum, 75th percentile, median, 25th percentile, and minimum, or as paired data points for each patient sample. Significance was calculated with a nonparametric paired <italic toggle="yes">t</italic> test with a two-tailed <italic toggle="yes">P</italic>-value (Wilcoxon&#8217;s test), or with Tukey&#8217;s multiple comparison test; variance was calculated as SD. The <italic toggle="yes">P</italic>-value cutoffs were set as * &lt; 0.05, ** &lt; 0.01, *** &lt; 0.001, **** &lt; 0.0001. If not significant, the <italic toggle="yes">P</italic>-value is not shown. Correlation plots were corrected for multiple comparison (n = 6) using the Bonferroni method.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="d67e340" position="float" orientation="portrait"><caption><title>Reviewer comments</title></caption><media xlink:href="LSA-2025-03249_review_history.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>We like to thank the Flow Cytometry Facility staff and the Department of Cryobiology from Sanquin, and the nursing staff and other employees involved from the Princess M&#225;xima Center. We thank Dr. John Haanen, Dr. Koen Hartemink, Dr. Kim Monkhorst, and Dr. Axel Bex from the Antonius van Leeuwenhoek ziekenhuis-Netherlands Cancer Institute for supporting our studies in adult solid tumors, and Aur&#233;lie Guislain for technical support. We also thank all patients and their parents for their willingness to contribute to science. This study was supported by an internal grant of Sanquin (PPOC 21-07) to MC Wolkers, by Oncode Institute to MC Wolkers, and by Stichting Kinder Kankervrij (KIKA 404 and KIKA 491) to J Wienke and MC Wolkers. The authors have no conflicting financial interests.</p><sec id="s17"><title>Author Contributions</title><p>
<list list-type="simple"><list-item><p>SM Castenmiller: conceptualization, formal analysis, and writing&#8212;original draft, review, and editing.</p></list-item><list-item><p>AL Borst: data curation, formal analysis, and writing&#8212;review and editing.</p></list-item><list-item><p>L Wardak: data curation and writing&#8212;review and editing.</p></list-item><list-item><p>JJ Molenaar: conceptualization.</p></list-item><list-item><p>M Papadopoulou: methodology and writing&#8212;review and editing.</p></list-item><list-item><p>RR de Krijger: project administration and writing&#8212;review and editing.</p></list-item><list-item><p>AFW van der Steeg: project administration and writing&#8212;review and editing.</p></list-item><list-item><p>MM van Noesel: project administration and writing&#8212;review and editing.</p></list-item><list-item><p>D Vermijlen: methodology and writing&#8212;review and editing.</p></list-item><list-item><p>R de Groot: conceptualization and writing&#8212;review and editing.</p></list-item><list-item><p>J Wienke: conceptualization, data curation, formal analysis, and writing&#8212;review and editing.</p></list-item><list-item><p>MC Wolkers: conceptualization, supervision, and writing&#8212;original draft.</p></list-item></list>
</p></sec><sec sec-type="COI-statement" id="s18"><title>Conflict of Interest Statement</title><p>The authors declare that they have no conflict of interest.</p></sec></ack><sec sec-type="data-availability" id="s19"><title>Data Availability</title><p>Because of privacy regulations, data are available upon reasonable request. Please contact MC Wolkers (<email>m.wolkers@sanquin.nl</email>).</p></sec><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Almeida</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Correia</surname><given-names>DV</given-names></string-name>, <string-name name-style="western"><surname>Fernandes-Platzgummer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>da Silva</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Da Silva</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Anjos</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Silva-Santos</surname><given-names>B</given-names></string-name></person-group> (<year>2016</year>) <article-title>Delta one T cells for immunotherapy of chronic lymphocytic leukemia: Clinical-grade expansion/differentiation and preclinical proof of concept</article-title>. <source>Clin Cancer Res</source><volume>22</volume>: <fpage>5795</fpage>&#8211;<lpage>5804</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-0597</pub-id><pub-id pub-id-type="pmid">27307596</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amaria</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Knisely</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vining</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kopetz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Overman</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Javle</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Antonoff</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Tzeng</surname><given-names>CWD</given-names></string-name>, <string-name name-style="western"><surname>Wolff</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Pant</surname><given-names>S</given-names></string-name>, <etal/></person-group> (<year>2024</year>) <article-title>Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma</article-title>. <source>J Immunother Cancer</source><volume>12</volume>: <fpage>e006822</fpage>. <pub-id pub-id-type="doi">10.1136/JITC-2023-006822</pub-id><pub-id pub-id-type="pmid">38309721</pub-id><pub-id pub-id-type="pmcid">PMC10840042</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Asten</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Groot</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Loenen</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Castenmiller</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Jong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Monkhorst</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Haanen</surname><given-names>JBAG</given-names></string-name>, <string-name name-style="western"><surname>Amsen</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bex</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Spaapen</surname><given-names>RM</given-names></string-name>, <etal/></person-group> (<year>2021</year>) <article-title>T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-&#947;, TNF-&#945; or IL-2 production</article-title>. <source>Oncoimmunology</source><volume>10</volume>: <fpage>1860482</fpage>. <pub-id pub-id-type="doi">10.1080/2162402X.2020.1860482</pub-id><pub-id pub-id-type="pmid">33537169</pub-id><pub-id pub-id-type="pmcid">PMC7833735</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Batchu</surname><given-names>S</given-names></string-name></person-group> (<year>2021</year>) <article-title>Immunological landscape of Neuroblastoma and its clinical significance</article-title>. <source>Cancer Treat Res Commun</source><volume>26</volume>: <fpage>100274</fpage>. <pub-id pub-id-type="doi">10.1016/J.CTARC.2020.100274</pub-id><pub-id pub-id-type="pmid">33338852</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ben-Avi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Farhi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ben-Nun</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gorodner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Greenberg</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Markel</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Schachter</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Itzhaki</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Besser</surname><given-names>MJ</given-names></string-name></person-group> (<year>2018</year>) <article-title>Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients</article-title>. <source>Cancer Immunol Immunother</source><volume>67</volume>: <fpage>1221</fpage>&#8211;<lpage>1230</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-018-2174-4</pub-id><pub-id pub-id-type="pmid">29845338</pub-id><pub-id pub-id-type="pmcid">PMC11028292</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Besser</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Shapira-Frommer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Treves</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Zippel</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Itzhaki</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Hershkovitz</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Levy</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kubi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hovav</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Chermoshniuk</surname><given-names>N</given-names></string-name>, <etal/></person-group> (<year>2010</year>) <article-title>Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients</article-title>. <source>Clin Cancer Res</source><volume>16</volume>: <fpage>2646</fpage>&#8211;<lpage>2655</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-0041</pub-id><pub-id pub-id-type="pmid">20406835</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cachot</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bilous</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Saillard</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cenerenti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rockinger</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Wyss</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Guillaume</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>J</given-names></string-name>, <etal/></person-group> (<year>2021</year>) <article-title>Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer</article-title>. <source>Sci Adv</source><volume>7</volume>: <fpage>eabe3348</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.abe3348</pub-id><pub-id pub-id-type="pmid">33637530</pub-id><pub-id pub-id-type="pmcid">PMC7909889</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Castenmiller</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>de Groot</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Guislain</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Monkhorst</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hartemink</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Veenhof</surname><given-names>AAFA</given-names></string-name>, <string-name name-style="western"><surname>Smit</surname><given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>Haanen</surname><given-names>JBAG</given-names></string-name>, <string-name name-style="western"><surname>Wolkers</surname><given-names>MC</given-names></string-name></person-group> (<year>2022</year>) <article-title>Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments</article-title>. <source>Immunooncol Technol</source><volume>15</volume>: <fpage>100090</fpage>. <pub-id pub-id-type="doi">10.1016/j.iotech.2022.100090</pub-id><pub-id pub-id-type="pmid">35965844</pub-id><pub-id pub-id-type="pmcid">PMC9372740</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Clark</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>PG</given-names></string-name></person-group> (<year>2020</year>) <article-title>A cell for the ages: Human &#947;&#948; T cells across the lifespan</article-title>. <source>Int J Mol Sci</source><volume>21</volume>: <fpage>8903</fpage>&#8211;<lpage>8918</lpage>. <pub-id pub-id-type="doi">10.3390/IJMS21238903</pub-id><pub-id pub-id-type="pmid">33255339</pub-id><pub-id pub-id-type="pmcid">PMC7727649</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Creelan</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Teer</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Toloza</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Landin</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Mullinax</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Saller</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Saltos</surname><given-names>AN</given-names></string-name>, <etal/></person-group> (<year>2021</year>) <article-title>Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: A phase 1 trial</article-title>. <source>Nat Med</source><volume>27</volume>: <fpage>1410</fpage>&#8211;<lpage>1418</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-021-01462-y</pub-id><pub-id pub-id-type="pmid">34385708</pub-id><pub-id pub-id-type="pmcid">PMC8509078</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Davey</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Willcox</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Joyce</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Ladell</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kasatskaya</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>McLaren</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Hunter</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Salim</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mohammed</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Price</surname><given-names>DA</given-names></string-name>, <etal/></person-group> (<year>2017</year>) <article-title>Clonal selection in the human V&#948;1 T cell repertoire indicates &#947;&#948; TCR-dependent adaptive immune surveillance</article-title>. <source>Nat Commun</source><volume>8</volume>: <fpage>14760</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms14760</pub-id><pub-id pub-id-type="pmid">28248310</pub-id><pub-id pub-id-type="pmcid">PMC5337994</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Davies</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kamdar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Woolf</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zlatareva</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Iannitto</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Morton</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Haque</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Biswas</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ndagire</surname><given-names>S</given-names></string-name>, <etal/></person-group> (<year>2024</year>) <article-title>PD-1 defines a distinct, functional, tissue-adapted state in V&#948;1+ T cells with implications for cancer immunotherapy</article-title>. <source>Nat Cancer</source><volume>5</volume>: <fpage>420</fpage>&#8211;<lpage>432</lpage>. <pub-id pub-id-type="doi">10.1038/S43018-023-00690-0</pub-id><pub-id pub-id-type="pmid">38172341</pub-id><pub-id pub-id-type="pmcid">PMC10965442</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De Groot</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Van Loenen</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Guislain</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nicolet</surname><given-names>BP</given-names></string-name>, <string-name name-style="western"><surname>Freen-Van Heeren</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Verhagen</surname><given-names>OJHM</given-names></string-name>, <string-name name-style="western"><surname>Van Den Heuvel</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>De Jong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Burger</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Van Der Schoot</surname><given-names>CE</given-names></string-name>, <etal/></person-group> (<year>2019</year>) <article-title>Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile</article-title>. <source>Oncoimmunology</source><volume>8</volume>: <fpage>e1648170</fpage>. <pub-id pub-id-type="doi">10.1080/2162402X.2019.1648170</pub-id><pub-id pub-id-type="pmid">31646094</pub-id><pub-id pub-id-type="pmcid">PMC6791436</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De Rosa</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Andrus</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Perfetto</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Mantovani</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Herzenberg</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Herzenberg</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Roederer</surname><given-names>M</given-names></string-name></person-group> (<year>2004</year>) <article-title>Ontogeny of gamma delta T cells in humans</article-title>. <source>J Immunol</source><volume>172</volume>: <fpage>1637</fpage>&#8211;<lpage>1645</lpage>. <pub-id pub-id-type="doi">10.4049/JIMMUNOL.172.3.1637</pub-id><pub-id pub-id-type="pmid">14734745</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de Vries</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>van de Haar</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Veninga</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Chalabi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ijsselsteijn</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>van der Ploeg</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>van den Bulk</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ruano</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>van den Berg</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Haanen</surname><given-names>JB</given-names></string-name>, <etal/></person-group> (<year>2023</year>) <article-title>&#947;&#948; T cells are effectors of immunotherapy in cancers with HLA class I defects</article-title>. <source>Nature</source><volume>613</volume>: <fpage>743</fpage>&#8211;<lpage>750</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-022-05593-1</pub-id><pub-id pub-id-type="pmid">36631610</pub-id><pub-id pub-id-type="pmcid">PMC9876799</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Donia</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kjeldsen</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Westergaard</surname><given-names>MCW</given-names></string-name>, <string-name name-style="western"><surname>Bianchi</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Legut</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Attaf</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Szomolay</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ott</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dolton</surname><given-names>G</given-names></string-name>, <etal/></person-group> (<year>2017</year>) <article-title>PD-1<sup>+</sup> polyfunctional T cells dominate the periphery after tumor-infiltrating lymphocyte therapy for cancer</article-title>. <source>Clin Cancer Res</source><volume>23</volume>: <fpage>5779</fpage>&#8211;<lpage>5788</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-1692</pub-id><pub-id pub-id-type="pmid">28679768</pub-id><pub-id pub-id-type="pmcid">PMC7115919</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dudley</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Gross</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Langhan</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Garcia</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Sherry</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Phan</surname><given-names>GQ</given-names></string-name>, <string-name name-style="western"><surname>Kammula</surname><given-names>US</given-names></string-name>, <string-name name-style="western"><surname>Hughes</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Citrin</surname><given-names>DE</given-names></string-name>, <etal/></person-group> (<year>2010</year>) <article-title>CD8+ enriched &#8220;young&#8221; tumor infiltrating lymphocytes can mediate regression of metastatic melanoma</article-title>. <source>Clin Cancer Res</source><volume>16</volume>: <fpage>6122</fpage>&#8211;<lpage>6131</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1297</pub-id><pub-id pub-id-type="pmid">20668005</pub-id><pub-id pub-id-type="pmcid">PMC2978753</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Flaadt</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ladenstein</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Ebinger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lode</surname><given-names>HN</given-names></string-name>, <string-name name-style="western"><surname>Arnard&#243;ttir</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Poetschger</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Schwinger</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Meisel</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schuster</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>D&#246;ring</surname><given-names>M</given-names></string-name>, <etal/></person-group> (<year>2023</year>) <article-title>Anti-GD2 antibody dinutuximab beta and low-dose interleukin 2 after haploidentical stem-cell transplantation in patients with relapsed neuroblastoma: A multicenter, phase I/II trial</article-title>. <source>J Clin Oncol</source><volume>41</volume>: <fpage>3135</fpage>&#8211;<lpage>3148</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.22.01630</pub-id><pub-id pub-id-type="pmid">36854071</pub-id><pub-id pub-id-type="pmcid">PMC10256422</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Giannoni</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Sanchez Sanchez</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Verdebout</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Papadopoulou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rezwani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ladell</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Miners</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>McLaren</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Fraser</surname><given-names>DJ</given-names></string-name>, <etal/></person-group> (<year>2024</year>) <article-title>Sepsis shapes the human &#947;&#948; TCR repertoire in an age- and pathogen-dependent manner</article-title>. <source>Eur J Immunol</source><volume>54</volume>: <fpage>e2451190</fpage>. <pub-id pub-id-type="doi">10.1002/EJI.202451190</pub-id><pub-id pub-id-type="pmid">39072722</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Girard</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Charles</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cluzel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Degeorges</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Manches</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Plumas</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>De Fraipont</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Leccia</surname><given-names>M-T</given-names></string-name>, <string-name name-style="western"><surname>Mouret</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chaperot</surname><given-names>L</given-names></string-name>, <etal/></person-group> (<year>2019</year>) <article-title>The features of circulating and tumor-infiltrating &#947;&#948; T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome</article-title>. <source>Oncoimmunology</source><volume>8</volume>: <fpage>1601483</fpage>. <pub-id pub-id-type="doi">10.1080/2162402X.2019.1601483</pub-id><pub-id pub-id-type="pmid">31413911</pub-id><pub-id pub-id-type="pmcid">PMC6682366</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gray</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Caron</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Wells</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Guyer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Szabo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rainbow</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ergen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rybkina</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bradley</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Matsumoto</surname><given-names>R</given-names></string-name>, <etal/></person-group> (<year>2024</year>) <article-title>Human &#947;&#948; T cells in diverse tissues exhibit site-specific maturation dynamics across the life span</article-title>. <source>Sci Immunol</source><volume>9</volume>: <fpage>eadn3954</fpage>. <pub-id pub-id-type="doi">10.1126/sciimmunol.adn3954</pub-id><pub-id pub-id-type="pmid">38848342</pub-id><pub-id pub-id-type="pmcid">PMC11425769</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hong</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Puaux</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Loumagne</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tow</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mackay</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pr&#233;vost-Blondel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Avril</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Nardin</surname><given-names>A</given-names></string-name>, <etal/></person-group> (<year>2011</year>) <article-title>Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control</article-title>. <source>Cancer Res</source><volume>71</volume>: <fpage>6997</fpage>&#8211;<lpage>7009</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1466</pub-id><pub-id pub-id-type="pmid">21948969</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Kabelitz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name></person-group> (<year>2023</year>) <article-title>&#947;&#948; T cells: Origin and fate, subsets, diseases and immunotherapy</article-title>. <source>Signal Transduct Target Ther</source><volume>8</volume>: <fpage>434</fpage>&#8211;<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1038/s41392-023-01653-8</pub-id><pub-id pub-id-type="pmid">37989744</pub-id><pub-id pub-id-type="pmcid">PMC10663641</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ji</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sha</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>F</given-names></string-name>, <etal/></person-group> (<year>2024</year>) <article-title>CD137 expression and signal function drive pleiotropic &#947;&#948; T-cell effector functions that inhibit intracellular M. tuberculosis growth</article-title>. <source>Clin Immunol</source><volume>266</volume>: <fpage>110331</fpage>. <pub-id pub-id-type="doi">10.1016/J.CLIM.2024.110331</pub-id><pub-id pub-id-type="pmid">39067675</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Vale</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Zacharakis</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Krishna</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Gasmi</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gartner</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Sindiri</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Malekzadeh</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Deniger</surname><given-names>DC</given-names></string-name>, <etal/></person-group> (<year>2022</year>) <article-title>Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor&#8211;engineered T cells targeting common p53 neoantigens in human solid tumors</article-title>. <source>Cancer Immunol Res</source><volume>10</volume>: <fpage>932</fpage>&#8211;<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1158/2326-6066.CIR-22-0040</pub-id><pub-id pub-id-type="pmid">35749374</pub-id><pub-id pub-id-type="pmcid">PMC9357191</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kruse</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Buzzai</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Shridhar</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Braun</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Gellert</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Knauth</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Pozniak</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Peters</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dittmann</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mengoni</surname><given-names>M</given-names></string-name>, <etal/></person-group> (<year>2023</year>) <article-title>CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours</article-title>. <source>Nature</source><volume>618</volume>: <fpage>1033</fpage>&#8211;<lpage>1040</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-023-06199-x</pub-id><pub-id pub-id-type="pmid">37316667</pub-id><pub-id pub-id-type="pmcid">PMC10307640</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ladenstein</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>P&#246;tschger</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Valteau-Couanet</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Luksch</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Castel</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Yaniv</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Laureys</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Brock</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Michon</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Owens</surname><given-names>C</given-names></string-name>, <etal/></person-group> (<year>2018</year>) <article-title>Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): A multicentre, randomised, phase 3 trial</article-title>. <source>Lancet Oncol</source><volume>19</volume>: <fpage>1617</fpage>&#8211;<lpage>1629</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(18)30578-3</pub-id><pub-id pub-id-type="pmid">30442501</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhuang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Heit</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Koo</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>IT</given-names></string-name>, <string-name name-style="western"><surname>Kwok</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>IB</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>DSW</given-names></string-name>, <string-name name-style="western"><surname>Simoni</surname><given-names>Y</given-names></string-name>, <etal/></person-group> (<year>2022</year>) <article-title>Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct</article-title>. <source>Oncoimmunology</source><volume>11</volume>: <fpage>2012961</fpage>. <pub-id pub-id-type="doi">10.1080/2162402X.2021.2012961</pub-id><pub-id pub-id-type="pmid">36524209</pub-id><pub-id pub-id-type="pmcid">PMC9746624</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>B</given-names></string-name>, <etal/></person-group> (<year>2023</year>) <article-title>Long-term survival of neuroblastoma patients receiving surgery, chemotherapy, and radiotherapy: A propensity score matching study</article-title>. <source>J Clin Med</source><volume>12</volume>: <fpage>754</fpage>. <pub-id pub-id-type="doi">10.3390/JCM12030754</pub-id><pub-id pub-id-type="pmid">36769402</pub-id><pub-id pub-id-type="pmcid">PMC9918249</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maris</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Hogarty</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Bagatell</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cohn</surname><given-names>SL</given-names></string-name></person-group> (<year>2007</year>) <article-title>Neuroblastoma</article-title>. <source>Lancet</source><volume>369</volume>: <fpage>2106</fpage>&#8211;<lpage>2120</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60983-0</pub-id><pub-id pub-id-type="pmid">17586306</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Masih</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Milewski</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>J</given-names></string-name></person-group> (<year>2021</year>) <article-title>Exploring and targeting the tumor immune microenvironment of neuroblastoma</article-title>. <source>J Cell Immunol</source><volume>3</volume>: <fpage>305</fpage>&#8211;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.33696/IMMUNOLOGY.3.111</pub-id><pub-id pub-id-type="pmid">35464627</pub-id><pub-id pub-id-type="pmcid">PMC9022637</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matthay</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Maris</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Schleiermacher</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Nakagawara</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mackall</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Diller</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>WA</given-names></string-name></person-group> (<year>2016</year>) <article-title>Neuroblastoma</article-title>. <source>Nat Rev Dis Primers</source><volume>2</volume>: <fpage>16078</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2016.78</pub-id><pub-id pub-id-type="pmid">27830764</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nicolet</surname><given-names>BP</given-names></string-name>, <string-name name-style="western"><surname>Guislain</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wolkers</surname><given-names>MC</given-names></string-name></person-group> (<year>2021</year>) <article-title>CD29 enriches for cytotoxic human CD4+ T cells</article-title>. <source>J Immunol</source><volume>207</volume>: <fpage>2966</fpage>&#8211;<lpage>2975</lpage>. <pub-id pub-id-type="doi">10.4049/JIMMUNOL.2100138</pub-id><pub-id pub-id-type="pmid">34782446</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oh</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Kwek</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Raju</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>McCarthy</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Aran</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ilano</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pai</surname><given-names>C-CS</given-names></string-name>, <string-name name-style="western"><surname>Rancan</surname><given-names>C</given-names></string-name>, <etal/></person-group> (<year>2020</year>) <article-title>Intratumoral CD4<sup>+</sup> T cells mediate anti-tumor cytotoxicity in human bladder cancer</article-title>. <source>Cell</source><volume>181</volume>: <fpage>1612</fpage>&#8211;<lpage>1625.e13</lpage>. <pub-id pub-id-type="doi">10.1016/J.CELL.2020.05.017</pub-id><pub-id pub-id-type="pmid">32497499</pub-id><pub-id pub-id-type="pmcid">PMC7321885</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oja</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Vieira Braga</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Remmerswaal</surname><given-names>EBM</given-names></string-name>, <string-name name-style="western"><surname>Kragten</surname><given-names>NAM</given-names></string-name>, <string-name name-style="western"><surname>Hertoghs</surname><given-names>KML</given-names></string-name>, <string-name name-style="western"><surname>Zuo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Moss</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>van Lier</surname><given-names>RAW</given-names></string-name>, <string-name name-style="western"><surname>van Gisbergen</surname><given-names>KPJM</given-names></string-name>, <string-name name-style="western"><surname>Hombrink</surname><given-names>P</given-names></string-name></person-group> (<year>2017</year>) <article-title>The transcription factor hobit identifies human cytotoxic CD4<sup>+</sup> T cells</article-title>. <source>Front Immunol</source><volume>8</volume>: <fpage>325</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2017.00325</pub-id><pub-id pub-id-type="pmid">28392788</pub-id><pub-id pub-id-type="pmcid">PMC5364140</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oll&#233; Hurtado</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wolbert</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fisher</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Flutter</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Stafford</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barton</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Barone</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Majani</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>J</given-names></string-name></person-group> (<year>2019</year>) <article-title>Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function</article-title>. <source>PLoS One</source><volume>14</volume>: <fpage>e0216373</fpage>. <pub-id pub-id-type="doi">10.1371/JOURNAL.PONE.0216373</pub-id><pub-id pub-id-type="pmid">31398192</pub-id><pub-id pub-id-type="pmcid">PMC6688820</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Papadopoulou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dimova</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Shey</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Briel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Veldtsman</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Khomba</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Africa</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Steyn</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hanekom</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Scriba</surname><given-names>TJ</given-names></string-name>, <etal/></person-group> (<year>2020a</year>) <article-title>Fetal public V&#947;9V&#948;2 T cells expand and gain potent cytotoxic functions early after birth</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>117</volume>: <fpage>18638</fpage>&#8211;<lpage>18648</lpage>. <pub-id pub-id-type="doi">10.1073/PNAS.1922595117</pub-id><pub-id pub-id-type="pmid">32665435</pub-id><pub-id pub-id-type="pmcid">PMC7414170</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Papadopoulou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sanchez Sanchez</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Vermijlen</surname><given-names>D</given-names></string-name></person-group> (<year>2020b</year>) <article-title>Innate and adaptive &#947;&#948; T cells: How, when, and why</article-title>. <source>Immunol Rev</source><volume>298</volume>: <fpage>99</fpage>&#8211;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1111/IMR.12926</pub-id><pub-id pub-id-type="pmid">33146423</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patel</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Sanjana</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Kishton</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Eidizadeh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vodnala</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Cam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gartner</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Steinberg</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname><given-names>TN</given-names></string-name>, <etal/></person-group> (<year>2017</year>) <article-title>Identification of essential genes for cancer immunotherapy</article-title>. <source>Nature</source><volume>548</volume>: <fpage>537</fpage>&#8211;<lpage>542</lpage>. <pub-id pub-id-type="doi">10.1038/NATURE23477</pub-id><pub-id pub-id-type="pmid">28783722</pub-id><pub-id pub-id-type="pmcid">PMC5870757</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pedersen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Westergaard</surname><given-names>MCW</given-names></string-name>, <string-name name-style="western"><surname>Milne</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nielsen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Borch</surname><given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Poulsen</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Hendel</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Kennedy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Briggs</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ledoux</surname><given-names>S</given-names></string-name>, <etal/></person-group> (<year>2018</year>) <article-title>Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: A pilot study</article-title>. <source>Oncoimmunology</source><volume>7</volume>: <fpage>e1502905</fpage>. <pub-id pub-id-type="doi">10.1080/2162402X.2018.1502905</pub-id><pub-id pub-id-type="pmid">30524900</pub-id><pub-id pub-id-type="pmcid">PMC6279323</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pei</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Mu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tu</surname><given-names>W</given-names></string-name></person-group> (<year>2020</year>) <article-title>CD137 costimulation enhances the antiviral activity of V&#947;9V&#948;2-T cells against influenza virus</article-title>. <source>Signal Transduct Target Ther</source><volume>5</volume>: <fpage>74</fpage>. <pub-id pub-id-type="doi">10.1038/S41392-020-0174-2</pub-id><pub-id pub-id-type="pmid">32488072</pub-id><pub-id pub-id-type="pmcid">PMC7266814</pub-id></mixed-citation></ref><ref id="bib42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Poch</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Joerger</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kodumudi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Beatty</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Innamarato</surname><given-names>PP</given-names></string-name>, <string-name name-style="western"><surname>Bunch</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Fishman</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sexton</surname><given-names>WJ</given-names></string-name>, <etal/></person-group> (<year>2018</year>) <article-title>Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer</article-title>. <source>Oncoimmunology</source><volume>7</volume>: <fpage>e1476816</fpage>. <pub-id pub-id-type="doi">10.1080/2162402X.2018.1476816</pub-id><pub-id pub-id-type="pmid">30228944</pub-id><pub-id pub-id-type="pmcid">PMC6140546</pub-id></mixed-citation></ref><ref id="bib43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pugh</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Morozova</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Attiyeh</surname><given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>Asgharzadeh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Auclair</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Cibulskis</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hanna</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kiezun</surname><given-names>A</given-names></string-name>, <etal/></person-group> (<year>2013</year>) <article-title>The genetic landscape of high-risk neuroblastoma</article-title>. <source>Nat Genet</source><volume>45</volume>: <fpage>279</fpage>&#8211;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1038/NG.2529</pub-id><pub-id pub-id-type="pmid">23334666</pub-id><pub-id pub-id-type="pmcid">PMC3682833</pub-id></mixed-citation></ref><ref id="bib44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ravens</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schultze-Florey</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Raha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sandrock</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Drenker</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Oberd&#246;rfer</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Reinhardt</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ravens</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Beck</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Geffers</surname><given-names>R</given-names></string-name>, <etal/></person-group> (<year>2017</year>) <article-title>Human &#947;&#948; T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection</article-title>. <source>Nat Immunol</source><volume>18</volume>: <fpage>393</fpage>&#8211;<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1038/NI.3686</pub-id><pub-id pub-id-type="pmid">28218745</pub-id></mixed-citation></ref><ref id="bib45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ravens</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fichtner</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Willers</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Torkornoo</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pirr</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sch&#246;ning</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Deseke</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sandrock</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bubke</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wilharm</surname><given-names>A</given-names></string-name>, <etal/></person-group> (<year>2020</year>) <article-title>Microbial exposure drives polyclonal expansion of innate &#947;&#948; T cells immediately after birth</article-title>. <source>Proc Natl Acad Sci U S A</source><volume>117</volume>: <fpage>18649</fpage>&#8211;<lpage>18660</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1922588117</pub-id><pub-id pub-id-type="pmid">32690687</pub-id><pub-id pub-id-type="pmcid">PMC7414158</pub-id></mixed-citation></ref><ref id="bib46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rohaan</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Borch</surname><given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>van den Berg</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Met</surname><given-names>&#214;</given-names></string-name>, <string-name name-style="western"><surname>Kessels</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Geukes Foppen</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Stoltenborg Granh&#248;j</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nuijen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Nijenhuis</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jedema</surname><given-names>I</given-names></string-name>, <etal/></person-group> (<year>2022</year>) <article-title>Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma</article-title>. <source>N Engl J Med</source><volume>387</volume>: <fpage>2113</fpage>&#8211;<lpage>2125</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMOA2210233</pub-id><pub-id pub-id-type="pmid">36477031</pub-id></mixed-citation></ref><ref id="bib47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rosenberg</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Restifo</surname><given-names>NP</given-names></string-name></person-group> (<year>2015</year>) <article-title>Adoptive cell transfer as personalized immunotherapy for human cancer</article-title>. <source>Science</source><volume>348</volume>: <fpage>62</fpage>&#8211;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1126/SCIENCE.AAA4967</pub-id><pub-id pub-id-type="pmid">25838374</pub-id><pub-id pub-id-type="pmcid">PMC6295668</pub-id></mixed-citation></ref><ref id="bib48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schatorj&#233;</surname><given-names>EJH</given-names></string-name>, <string-name name-style="western"><surname>Gemen</surname><given-names>EFA</given-names></string-name>, <string-name name-style="western"><surname>Driessen</surname><given-names>GJA</given-names></string-name>, <string-name name-style="western"><surname>Leuvenink</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>van Hout</surname><given-names>RWNM</given-names></string-name>, <string-name name-style="western"><surname>de Vries</surname><given-names>E</given-names></string-name></person-group> (<year>2012</year>) <article-title>Paediatric reference values for the peripheral T cell compartment</article-title>. <source>Scand J Immunol</source><volume>75</volume>: <fpage>436</fpage>&#8211;<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-3083.2012.02671.x</pub-id><pub-id pub-id-type="pmid">22420532</pub-id></mixed-citation></ref><ref id="bib49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schmiedeberg</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Krause</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>R&#246;hl</surname><given-names>FW</given-names></string-name>, <string-name name-style="western"><surname>Hartig</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jorch</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Brunner-Weinzierl</surname><given-names>MC</given-names></string-name></person-group> (<year>2016</year>) <article-title>T cells of infants are mature, but hyporeactive due to limited Ca2+ influx</article-title>. <source>PLoS One</source><volume>11</volume>: <fpage>e0166633</fpage>. <pub-id pub-id-type="doi">10.1371/JOURNAL.PONE.0166633</pub-id><pub-id pub-id-type="pmid">27893767</pub-id><pub-id pub-id-type="pmcid">PMC5125607</pub-id></mixed-citation></ref><ref id="bib50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Silva-Santos</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Strid</surname><given-names>J</given-names></string-name></person-group> (<year>2018</year>) <article-title>Working in &#8216;NK mode&#8217;: Natural killer group 2 member D and natural cytotoxicity receptors in stress-surveillance by &#947;&#948; T cells</article-title>. <source>Front Immunol</source><volume>9</volume>: <fpage>851</fpage>. <pub-id pub-id-type="doi">10.3389/FIMMU.2018.00851</pub-id><pub-id pub-id-type="pmid">29740448</pub-id><pub-id pub-id-type="pmcid">PMC5928212</pub-id></mixed-citation></ref><ref id="bib51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Simoni</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Becht</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Fehlings</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Loh</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Koo</surname><given-names>S-LL</given-names></string-name>, <string-name name-style="western"><surname>Teng</surname><given-names>KWW</given-names></string-name>, <string-name name-style="western"><surname>Yeong</surname><given-names>JPS</given-names></string-name>, <string-name name-style="western"><surname>Nahar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kared</surname><given-names>H</given-names></string-name>, <etal/></person-group> (<year>2018</year>) <article-title>Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates</article-title>. <source>Nature</source><volume>557</volume>: <fpage>575</fpage>&#8211;<lpage>579</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-018-0130-2</pub-id><pub-id pub-id-type="pmid">29769722</pub-id></mixed-citation></ref><ref id="bib52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sistigu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yamazaki</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Vacchelli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Chaba</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Enot</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Adam</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vitale</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Goubar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Baracco</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Rem&#233;dios</surname><given-names>C</given-names></string-name>, <etal/></person-group> (<year>2014</year>) <article-title>Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy</article-title>. <source>Nat Med</source><volume>20</volume>: <fpage>1301</fpage>&#8211;<lpage>1309</lpage>. <pub-id pub-id-type="doi">10.1038/NM.3708</pub-id><pub-id pub-id-type="pmid">25344738</pub-id></mixed-citation></ref><ref id="bib53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Theruvath</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Menard</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>BAH</given-names></string-name>, <string-name name-style="western"><surname>Linde</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Coles</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Dalton</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kiru</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Delaidelli</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sotillo</surname><given-names>E</given-names></string-name>, <etal/></person-group> (<year>2022</year>) <article-title>Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication</article-title>. <source>Nat Med</source><volume>28</volume>: <fpage>333</fpage>&#8211;<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1038/S41591-021-01625-X</pub-id><pub-id pub-id-type="pmid">35027753</pub-id><pub-id pub-id-type="pmcid">PMC9098186</pub-id></mixed-citation></ref><ref id="bib54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thome</surname><given-names>JJC</given-names></string-name>, <string-name name-style="western"><surname>Bickham</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Ohmura</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kubota</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Matsuoka</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Granot</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Griesemer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lerner</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>T</given-names></string-name>, <etal/></person-group> (<year>2016</year>) <article-title>Early-life compartmentalization of human T cell differentiation and regulatory function in mucosal and lymphoid tissues</article-title>. <source>Nat Med</source><volume>22</volume>: <fpage>72</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4008</pub-id><pub-id pub-id-type="pmid">26657141</pub-id><pub-id pub-id-type="pmcid">PMC4703455</pub-id></mixed-citation></ref><ref id="bib55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thommen</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Koelzer</surname><given-names>VH</given-names></string-name>, <string-name name-style="western"><surname>Herzig</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Roller</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Trefny</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dimeloe</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kiialainen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hanhart</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schill</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hess</surname><given-names>C</given-names></string-name>, <etal/></person-group> (<year>2018</year>) <article-title>A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade</article-title>. <source>Nat Med</source><volume>24</volume>: <fpage>994</fpage>&#8211;<lpage>1004</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-018-0057-z</pub-id><pub-id pub-id-type="pmid">29892065</pub-id><pub-id pub-id-type="pmcid">PMC6110381</pub-id></mixed-citation></ref><ref id="bib56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van den Berg</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Heemskerk</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>van Rooij</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gomez-Eerland</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Michels</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>van Zon</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>de Boer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bakker</surname><given-names>NAM</given-names></string-name>, <string-name name-style="western"><surname>Jorritsma-Smit</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>van Buuren</surname><given-names>MM</given-names></string-name>, <etal/></person-group> (<year>2020</year>) <article-title>Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: Boosting of neoantigen-specific T cell reactivity and long-term follow-up</article-title>. <source>J Immunother Cancer</source><volume>8</volume>: <fpage>e000848</fpage>. <pub-id pub-id-type="doi">10.1136/JITC-2020-000848</pub-id><pub-id pub-id-type="pmid">32753545</pub-id><pub-id pub-id-type="pmcid">PMC7406109</pub-id></mixed-citation></ref><ref id="bib57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Verhoeven</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Mei</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Olsen</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Gustafsson</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Valind</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lindstr&#246;m</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gisselsson</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fard</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Hagerling</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kharchenko</surname><given-names>PV</given-names></string-name>, <etal/></person-group> (<year>2022</year>) <article-title>The immune cell atlas of human neuroblastoma</article-title>. <source>Cell Rep Med</source><volume>3</volume>: <fpage>100657</fpage>. <pub-id pub-id-type="doi">10.1016/J.XCRM.2022.100657</pub-id><pub-id pub-id-type="pmid">35688160</pub-id><pub-id pub-id-type="pmcid">PMC9245004</pub-id></mixed-citation></ref><ref id="bib58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Verkerk</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pappot</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Jorritsma</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Duurland</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Spaapen</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>van Ham</surname><given-names>SM</given-names></string-name></person-group> (<year>2024</year>) <article-title>Isolation and expansion of pure and functional &#947;&#948; T cells</article-title>. <source>Front Immunol</source><volume>15</volume>: <fpage>1336870</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2024.1336870</pub-id><pub-id pub-id-type="pmid">38426099</pub-id><pub-id pub-id-type="pmcid">PMC10902048</pub-id></mixed-citation></ref><ref id="bib59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vermijlen</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gatti</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kouzeli</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rus</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Eberl</surname><given-names>M</given-names></string-name></person-group> (<year>2018</year>) <article-title>&#947;&#948; T cell responses: How many ligands will it take till we know?</article-title><source>Semin Cell Dev Biol</source><volume>84</volume>: <fpage>75</fpage>&#8211;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/J.SEMCDB.2017.10.009</pub-id><pub-id pub-id-type="pmid">29402644</pub-id></mixed-citation></ref><ref id="bib60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wienke</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dierselhuis</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Tytgat</surname><given-names>GAM</given-names></string-name>, <string-name name-style="western"><surname>K&#252;nkele</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nierkens</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Molenaar</surname><given-names>JJ</given-names></string-name></person-group> (<year>2021</year>) <article-title>The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology</article-title>. <source>Eur J Cancer</source><volume>144</volume>: <fpage>123</fpage>&#8211;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1016/J.EJCA.2020.11.014</pub-id><pub-id pub-id-type="pmid">33341446</pub-id></mixed-citation></ref><ref id="bib61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>W&#246;lfl</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Garrido</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cabrera</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Meyen-Southard</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Spitz</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ernestus</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Berthold</surname><given-names>F</given-names></string-name></person-group> (<year>2005</year>) <article-title>Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma</article-title>. <source>Cancer Immunol Immunother</source><volume>54</volume>: <fpage>400</fpage>&#8211;<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1007/S00262-004-0603-Z</pub-id><pub-id pub-id-type="pmid">15449039</pub-id><pub-id pub-id-type="pmcid">PMC11034322</pub-id></mixed-citation></ref><ref id="bib62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kyle-Cezar</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Woolf</surname><given-names>RT</given-names></string-name>, <string-name name-style="western"><surname>Naceur-Lombardelli</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Owen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Biswas</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lorenc</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vantourout</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gazinska</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Grigoriadis</surname><given-names>A</given-names></string-name>, <etal/></person-group> (<year>2019</year>) <article-title>An innate-like V&#948;1+ &#947;&#948; T cell compartment in the human breast is associated with remission in triple-negative breast cancer</article-title>. <source>Sci Transl Med</source><volume>11</volume>: <fpage>eaax9364</fpage>. <pub-id pub-id-type="doi">10.1126/SCITRANSLMED.AAX9364</pub-id><pub-id pub-id-type="pmid">31597756</pub-id><pub-id pub-id-type="pmcid">PMC6877350</pub-id></mixed-citation></ref><ref id="bib63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Biswas</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Usaite</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Angelova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Boeing</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Karasaki</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Veeriah</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Czyzewska-Khan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Morton</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Joseph</surname><given-names>M</given-names></string-name>, <etal/></person-group> (<year>2022</year>) <article-title>A local human V&#948;1 T cell population is associated with survival in nonsmall-cell lung cancer</article-title>. <source>Nat Cancer</source><volume>3</volume>: <fpage>696</fpage>&#8211;<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1038/S43018-022-00376-Z</pub-id><pub-id pub-id-type="pmid">35637401</pub-id><pub-id pub-id-type="pmcid">PMC9236901</pub-id></mixed-citation></ref><ref id="bib64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ye</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>D-G</given-names></string-name>, <string-name name-style="western"><surname>Poussin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Best</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Coukos</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>DJ</given-names>, <suffix>Jr</suffix></string-name></person-group> (<year>2014</year>) <article-title>CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor</article-title>. <source>Clin Cancer Res</source><volume>20</volume>: <fpage>44</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-0945</pub-id><pub-id pub-id-type="pmid">24045181</pub-id><pub-id pub-id-type="pmcid">PMC3947326</pub-id></mixed-citation></ref><ref id="bib65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Gilman</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Ozkaynak</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>London</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Kreissman</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>HX</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Villablanca</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Matthay</surname><given-names>KK</given-names></string-name>, <etal/></person-group> (<year>2010</year>) <article-title>Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma</article-title>. <source>N Engl J Med</source><volume>363</volume>: <fpage>1324</fpage>&#8211;<lpage>1334</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMOA0911123</pub-id><pub-id pub-id-type="pmid">20879881</pub-id><pub-id pub-id-type="pmcid">PMC3086629</pub-id></mixed-citation></ref><ref id="bib66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zacharakis</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chinnasamy</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Black</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Pasetto</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Langhan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shelton</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Prickett</surname><given-names>T</given-names></string-name>, <etal/></person-group> (<year>2018</year>) <article-title>Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer</article-title>. <source>Nat Med</source><volume>24</volume>: <fpage>724</fpage>&#8211;<lpage>730</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-018-0040-8</pub-id><pub-id pub-id-type="pmid">29867227</pub-id><pub-id pub-id-type="pmcid">PMC6348479</pub-id></mixed-citation></ref><ref id="bib67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zacharakis</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Huq</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Seitter</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Gartner</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Sindiri</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>YF</given-names></string-name>, <string-name name-style="western"><surname>Paria</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Ray</surname><given-names>S</given-names></string-name>, <etal/></person-group> (<year>2022</year>) <article-title>Breast cancers are immunogenic: Immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes</article-title>. <source>J Clin Oncol</source><volume>40</volume>: <fpage>1741</fpage>&#8211;<lpage>1754</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.21.02170</pub-id><pub-id pub-id-type="pmid">35104158</pub-id><pub-id pub-id-type="pmcid">PMC9148699</pub-id></mixed-citation></ref><ref id="bib68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zappa</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Vitali</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Anders</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Molenaar</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Wienke</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>K&#252;nkele</surname><given-names>A</given-names></string-name></person-group> (<year>2023</year>) <article-title>Adoptive cell therapy in paediatric extracranial solid tumours: Current approaches and future challenges</article-title>. <source>Eur J Cancer</source><volume>194</volume>: <fpage>113347</fpage>. <pub-id pub-id-type="doi">10.1016/J.EJCA.2023.113347</pub-id><pub-id pub-id-type="pmid">37832507</pub-id><pub-id pub-id-type="pmcid">PMC10695178</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>